cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 18, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is Atezolizumab therapy likely to be beneficial?","In a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 18, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is Atezolizumab therapy likely to be beneficial? Review the patient's transcriptomic data and run the Compass analysis to assess the likely response to immune checkpoint inhibitor (ICI) therapy. Examine the Compass output carefully, focusing on key immune markers such as macrophage activity, IFNG pathway expression, genomic integrity, cell proliferation, and cytotoxic T-cell levels. Then, combine these data with the overall Compass prediction and relevant patient metadata to develop a detailed summary of the patient’s immune profile. Based on this integrated assessment, provide a comprehensive rationale that supports the classification of the patient as a likely responder or non-responder to ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutation burden (TMB) of 1.0. Based on these findings, what is your assessment regarding his likelihood to respond to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutation burden (TMB) of 1.0. Based on these findings, what is your assessment regarding his likelihood to respond to atezolizumab therapy? Review the patient's transcriptomic profile and perform the Compass analysis to predict their response to immune checkpoint inhibitor therapy. Specifically, evaluate the Compass results with attention to markers such as macrophage activity, IFNG pathway expression, genomic stability, cell proliferation, and cytotoxic T-cell levels. Then, integrate these findings with the overall Compass prediction and the patient’s clinical metadata to construct a detailed immune profile. Finally, based on this integrated analysis, provide a clear rationale for categorizing the patient as either a likely responder or non-responder to ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden of 44.0 mutations per megabase. Based on these findings, what is the likelihood that she will respond favorably to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden of 44.0 mutations per megabase. Based on these findings, what is the likelihood that she will respond favorably to Atezolizumab therapy? Review the patient's transcriptomic data and complete a Compass analysis to estimate their potential response to immune checkpoint inhibitor therapy. In this analysis, pay particular attention to markers such as macrophage activity, IFNG pathway expression, genomic stability, cell proliferation, and cytotoxic T-cell levels. Then, combine these findings with the overall Compass prediction and the patient’s clinical data to develop a comprehensive immune profile. Finally, based on this integrative evaluation, provide a clear rationale for classifying the patient as either a likely responder or non-responder to ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"For a white female patient with bladder urothelial carcinoma whose lymph node biopsy reveals a tumor mutational burden (TMB) of 2.0, how would you assess her potential response to atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma whose lymph node biopsy reveals a tumor mutational burden (TMB) of 2.0, how would you assess her potential response to atezolizumab therapy? Review the patient's transcriptomic data and perform a Compass analysis to assess their potential response to immune checkpoint inhibitor (ICI) therapy. In this process, meticulously evaluate markers including macrophage activity, IFNG pathway expression, genomic stability, cell proliferation, and cytotoxic T-cell levels. Integrate these results with the overall Compass prediction and the patient’s clinical data to construct a comprehensive immune profile. Finally, use this combined information to clearly justify whether the patient is likely to be a responder or non-responder to ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"I have a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy shows a tumor mutational burden (TMB) of 8.0. Based on these findings, do you anticipate he would likely benefit from Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy shows a tumor mutational burden (TMB) of 8.0. Based on these findings, do you anticipate he would likely benefit from Atezolizumab therapy? Review the patient's transcriptomic data and conduct a Compass analysis to evaluate their likely response to immune checkpoint inhibitor therapy. In this analysis, carefully assess key markers such as macrophage activity, IFNG pathway expression, genomic stability, cell proliferation, and the levels of cytotoxic T cells. Then, integrate these findings with the overall Compass prediction and the patient’s clinical information to create a detailed immune profile. Finally, use this comprehensive profile to clearly explain whether the patient is expected to respond to ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of her tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 6.0. Could you help assess her potential response to atezolizumab therapy?,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of her tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 6.0. Could you help assess her potential response to atezolizumab therapy? Examine the patient's transcriptomic data and perform a Compass analysis to predict their potential response to immune checkpoint inhibitor therapy. In your evaluation, focus on critical markers including macrophage activity, IFNG pathway expression, genomic stability, cell proliferation, and cytotoxic T cell levels. Integrate these results with the overall Compass prediction and the patient's clinical profile to develop a comprehensive immune profile, which should then be used to explain whether the patient is likely to benefit from ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"I am managing a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutation burden of 11.0 mutations per megabase. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","I am managing a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutation burden of 11.0 mutations per megabase. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Please review the patient’s transcriptomic data and perform a Compass analysis to assess their likely response to immune checkpoint inhibitor (ICI) therapy. As part of this evaluation, pay particular attention to markers such as macrophage activity, IFNG pathway expression, genomic stability, cell proliferation, and cytotoxic T cell levels. Then, integrate these findings with the overall Compass prediction and the patient’s clinical profile to formulate a detailed immune profile that will help determine whether the patient is expected to benefit from ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"In a white male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden (TMB) of 18.0. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden (TMB) of 18.0. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Review the patient’s transcriptomic data and conduct a Compass analysis to evaluate their prospective response to immune checkpoint inhibitor therapy. In your assessment, focus on key markers including macrophage function, IFNG pathway expression, genomic stability, cell proliferation, and cytotoxic T cell levels. Once these data points have been analyzed, integrate the results with the overall Compass score and the patient’s clinical profile to develop a comprehensive immune profile. This profile will be used to determine the likelihood of the patient benefiting from ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"In a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy reports a tumor mutational burden (TMB) value of nan. Based on this information, can we reliably predict her likely response to atezolizumab therapy?","In a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy reports a tumor mutational burden (TMB) value of nan. Based on this information, can we reliably predict her likely response to atezolizumab therapy? Examine the patient’s transcriptomic data and perform a Compass analysis to assess their potential response to immune checkpoint inhibitor therapy. Focus your evaluation on markers related to macrophage function, IFNG pathway activity, genomic stability, cell proliferation, and cytotoxic T cell levels. Then, integrate these findings with the overall Compass score and the patient’s clinical details to formulate a comprehensive immune profile. This profile will help predict the likelihood of the patient benefiting from ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled via nanobiopsy. The report noted a tumor mutational burden (TMB) value of ""nan."" Based on this information, can we assess the likelihood of his response to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled via nanobiopsy. The report noted a tumor mutational burden (TMB) value of ""nan."" Based on this information, can we assess the likelihood of his response to atezolizumab therapy? Review the patient’s transcriptomic profile and perform a Compass analysis to evaluate their potential response to immune checkpoint inhibitors. In your assessment, concentrate on markers indicating macrophage function, IFNG pathway activity, genomic stability, cell proliferation, and cytotoxic T cell levels. Then, combine these findings with the overall Compass score and the patient’s clinical history to create an integrated immune profile. This comprehensive profile will help determine the likelihood that the patient will benefit from immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"I am managing a Caucasian male patient with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment, obtained from a kidney biopsy, revealed a tumor mutational burden (TMB) of 2.0 mutations per megabase. Based on these findings, could you provide an assessment of his likelihood of responding to Atezolizumab therapy?","I am managing a Caucasian male patient with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment, obtained from a kidney biopsy, revealed a tumor mutational burden (TMB) of 2.0 mutations per megabase. Based on these findings, could you provide an assessment of his likelihood of responding to Atezolizumab therapy? Please examine the patient’s transcriptomic data and perform a Compass analysis to evaluate their potential response to immune checkpoint inhibitor treatment. In your review, focus on biomarkers related to macrophage function, IFNG pathway activity, genomic stability, cell proliferation, and cytotoxic T cell presence. Once these parameters are assessed, integrate the findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immune profile. This profile should guide predictions about the patient’s likelihood of benefiting from immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. A bladder biopsy and subsequent transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 8. Based on these findings, is it likely that the patient would respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. A bladder biopsy and subsequent transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 8. Based on these findings, is it likely that the patient would respond to Atezolizumab therapy? Review the patient's transcriptomic data using the Compass analysis to assess their likely response to immune checkpoint inhibitor therapy. Specifically, evaluate biomarkers that indicate macrophage activity, the IFNG pathway, genomic stability, cell proliferation, and the abundance of cytotoxic T cells. Then, integrate these findings with the overall Compass score and the patient’s clinical background to create a detailed immune profile that can inform predictions regarding the effectiveness of immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"I am evaluating a white female patient with bladder urothelial carcinoma. A transcriptomic analysis from a lymph node biopsy of her tumor immune microenvironment reported a tumor mutation burden (TMB) value of ""nan"". How should we interpret this result in terms of predicting her potential response to Atezolizumab therapy?","I am evaluating a white female patient with bladder urothelial carcinoma. A transcriptomic analysis from a lymph node biopsy of her tumor immune microenvironment reported a tumor mutation burden (TMB) value of ""nan"". How should we interpret this result in terms of predicting her potential response to Atezolizumab therapy? Review the patient's transcriptomic data using the Compass platform to determine their potential response to immune checkpoint inhibitor therapy. Specifically, assess biomarkers related to macrophage activity, the interferon-gamma pathway, genomic stability, cell proliferation, and the number of cytotoxic T cells. Then, correlate these findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immune profile that aids in predicting the effectiveness of immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"In a white male patient with bladder urothelial carcinoma, a ureter biopsy revealed a tumor mutational burden of 9.0. Based on this molecular profile, how likely is it that the patient will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a ureter biopsy revealed a tumor mutational burden of 9.0. Based on this molecular profile, how likely is it that the patient will respond to atezolizumab therapy? Please analyze the patient's transcriptomic data on the Compass platform to evaluate their likely response to immune checkpoint inhibitor therapy. Focus on biomarkers that indicate macrophage function, activity in the interferon-gamma pathway, genomic stability, cell proliferation, and the density of cytotoxic T cells. Then, integrate these findings with the overall Compass score and the patient's clinical history to build a detailed immune profile that can help predict the efficacy of immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"For a Caucasian female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile reveals a tumor mutation burden (TMB) of 4.0, how likely is she to benefit from Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile reveals a tumor mutation burden (TMB) of 4.0, how likely is she to benefit from Atezolizumab therapy? Review the patient’s transcriptomic profile on the Compass platform to assess their potential benefit from immune checkpoint inhibitor therapy. Focus your analysis on biomarkers that inform macrophage activity, interferon-gamma pathway signal strength, genomic stability, cell proliferation, and the presence of cytotoxic T cells. Then, combine these insights with the overall Compass score and the patient’s clinical history to construct a comprehensive immune profile that could predict treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a ureteral biopsy revealed a tumor mutational burden (TMB) of 32 mutations per megabase. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a ureteral biopsy revealed a tumor mutational burden (TMB) of 32 mutations per megabase. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please examine the patient's transcriptomic data on the Compass platform to evaluate their eligibility for immune checkpoint inhibitor therapy. Specifically, analyze biomarkers related to macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and the presence of cytotoxic T cells. Then, integrate these findings with the overall Compass score and the patient's clinical history to develop a detailed immune profile that may help predict their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"A white male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 21.0 based on transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy. Given this molecular profile, how likely is the patient to respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 21.0 based on transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy. Given this molecular profile, how likely is the patient to respond to Atezolizumab therapy? Review the patient's transcriptomic data available on the Compass platform to determine eligibility for immune checkpoint inhibitor therapy. In your evaluation, focus on biomarkers that indicate macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell presence. After gathering these findings, combine them with the overall Compass score and the patient's clinical history to develop a comprehensive immune profile that may predict their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"We have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment, analyzed through transcriptomic profiling of a kidney biopsy sample, shows a tumor mutation burden of 10.0. Based on these findings, is it likely that the patient would respond favorably to Atezolizumab therapy?","We have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment, analyzed through transcriptomic profiling of a kidney biopsy sample, shows a tumor mutation burden of 10.0. Based on these findings, is it likely that the patient would respond favorably to Atezolizumab therapy? Please review the patient's transcriptomic data on the Compass platform to assess their eligibility for immune checkpoint inhibitors. Focus on identifying biomarkers associated with macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell levels. Then, integrate these findings with the overall Compass score and the patient's clinical history to construct a detailed immune profile that can help predict their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"For a white male patient with bladder urothelial carcinoma, whose tumor biopsy revealed a tumor mutational burden (TMB) of 38.0 through transcriptomic profiling of the tumor immune microenvironment, would you expect a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor biopsy revealed a tumor mutational burden (TMB) of 38.0 through transcriptomic profiling of the tumor immune microenvironment, would you expect a favorable response to Atezolizumab therapy? Please examine the patient’s transcriptomic data available on the Compass platform to determine their suitability for immune checkpoint inhibitor therapy. While reviewing the data, carefully assess biomarkers indicative of macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell presence. After this evaluation, combine your findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immune profile that may predict their response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"In a white female patient with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis revealed a tumor mutational burden (TMB) of 7.0. Based on this information, what is the likelihood of her responding to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis revealed a tumor mutational burden (TMB) of 7.0. Based on this information, what is the likelihood of her responding to Atezolizumab therapy? Review the patient’s transcriptomic data on the Compass platform to assess their eligibility for immune checkpoint inhibitor therapy. Focus on evaluating biomarkers that reflect macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and the presence of cytotoxic T-cells. Once you have completed this review, integrate your findings with the overall Compass score and the patient’s clinical history to create a detailed immune profile that may help predict their response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"In a White male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis shows a tumor mutation burden (TMB) of 5.0, what is the likelihood of a clinical response to atezolizumab therapy?","In a White male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis shows a tumor mutation burden (TMB) of 5.0, what is the likelihood of a clinical response to atezolizumab therapy? Please review the patient’s transcriptomic data available on the Compass platform to determine their suitability for immune checkpoint inhibitor therapy. While evaluating the data, be sure to focus on biomarkers that indicate macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and the density of cytotoxic T-cells. Once your analysis is complete, combine these findings with the patient’s overall Compass score and clinical history to develop a comprehensive immune profile that can help anticipate their response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"A white male patient diagnosed with bladder urothelial carcinoma (BLCA) has a transcriptomic profile from a bladder biopsy showing a tumor mutational burden (TMB) of 15.0. Based on this information, is there an indication that the patient may respond favorably to Atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma (BLCA) has a transcriptomic profile from a bladder biopsy showing a tumor mutational burden (TMB) of 15.0. Based on this information, is there an indication that the patient may respond favorably to Atezolizumab therapy? Please access the patient's transcriptomic data on the Compass platform and assess its suitability for immune checkpoint inhibitor therapy. Focus your evaluation on key biomarkers related to macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and the density of cytotoxic T-cells. Afterwards, integrate these molecular findings with the patient's overall Compass score and clinical history to construct a comprehensive immune profile that may help predict their response to the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic evaluation of his tumor immune microenvironment. The analysis did not yield a measurable tumor mutational burden. Based on these findings, what is the likelihood that he would respond to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic evaluation of his tumor immune microenvironment. The analysis did not yield a measurable tumor mutational burden. Based on these findings, what is the likelihood that he would respond to Atezolizumab therapy? Please review the patient's transcriptomic profile on the Compass platform to determine their potential suitability for immune checkpoint inhibitor therapy. In your analysis, pay particular attention to biomarkers indicating macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and the abundance of cytotoxic T-cells. Once these molecular markers are evaluated, integrate your findings with the patient's overall Compass score and clinical history to develop a comprehensive immune profile that may help predict their therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/181b63-ar-181b638.pkl. "
BLCA,,,,NR,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, performed on a lung biopsy, reported a tumor mutational burden value as ‘nan’. Could you help evaluate whether he is likely to respond to Atezolizumab therapy based on these findings?","I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, performed on a lung biopsy, reported a tumor mutational burden value as ‘nan’. Could you help evaluate whether he is likely to respond to Atezolizumab therapy based on these findings? Review the patient's transcriptomic data on the Compass platform to assess their eligibility for immune checkpoint inhibitor therapy. Focus on key biomarkers, including indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and levels of cytotoxic T-cells. After evaluating these molecular markers, combine your insights with the patient’s overall Compass score and clinical history to construct a detailed immune profile that could help predict their treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 18. Based on this information, can we predict whether the patient is likely to respond favorably to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 18. Based on this information, can we predict whether the patient is likely to respond favorably to Atezolizumab therapy? Please examine the patient's transcriptomic data on the Compass platform to determine their suitability for immune checkpoint inhibitor therapy. In your review, specifically assess biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell levels. Then, integrate these findings with the patient’s overall Compass score and their clinical history to develop a comprehensive immune profile that may predict their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"In a Black/African American male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment—assessed via transcriptomic profiling from a ureter biopsy—shows a tumor mutational burden (TMB) of 7.0, how likely is the patient to respond to atezolizumab therapy?","In a Black/African American male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment—assessed via transcriptomic profiling from a ureter biopsy—shows a tumor mutational burden (TMB) of 7.0, how likely is the patient to respond to atezolizumab therapy? Review the patient’s transcriptomic data on the Compass platform to evaluate their eligibility for immune checkpoint inhibitor therapy. Focus on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell levels. Then, combine these data with the overall Compass score and the patient’s clinical history to generate a comprehensive immune profile that can help predict their treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"A Caucasian male diagnosed with bladder urothelial carcinoma underwent a bladder biopsy, and the transcriptomic profile of his tumor immune microenvironment revealed a tumor mutational burden of 19.0. Given this information, what is your assessment of his likely response to atezolizumab therapy?","A Caucasian male diagnosed with bladder urothelial carcinoma underwent a bladder biopsy, and the transcriptomic profile of his tumor immune microenvironment revealed a tumor mutational burden of 19.0. Given this information, what is your assessment of his likely response to atezolizumab therapy? Review the patient's transcriptomic data available on the Compass platform to determine their suitability for immune checkpoint inhibitor therapy. Concentrate on key biomarkers such as those related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell levels. Next, integrate these findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immune profile that can inform predictions about their treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"In a white male patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 5.0. Based on these findings, what is the likelihood that he would respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 5.0. Based on these findings, what is the likelihood that he would respond to Atezolizumab therapy? Examine the patient's transcriptomic data on the Compass platform to assess whether they are a good candidate for immune checkpoint inhibitor therapy. Focus on important biomarkers, including those related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell presence. Combine these molecular findings with the overall Compass score and the patient's clinical history to build a detailed immune profile, which will help predict their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a tumor mutation burden of 5.0. Based on the transcriptomic profile of the tumor immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a tumor mutation burden of 5.0. Based on the transcriptomic profile of the tumor immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy? Review the patient's transcriptomic data on the Compass platform to determine their suitability for immune checkpoint inhibitor therapy. Specifically, assess biomarkers linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell presence. Combine these molecular insights with the overall Compass score and the patient's clinical history to construct a comprehensive immune profile, which will assist in predicting their treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has revealed a tumor mutational burden of 8.0 mutations per megabase. How might this TMB value impact the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has revealed a tumor mutational burden of 8.0 mutations per megabase. How might this TMB value impact the likelihood of a favorable response to Atezolizumab therapy? Please review the patient's transcriptomic data available on the Compass platform to evaluate their potential for immune checkpoint inhibitor therapy. In your analysis, focus on biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the overall Compass score and the patient's clinical history to develop a comprehensive immune profile that can help predict their treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma (BLCA). Analysis of the tumor immune microenvironment from a ureter biopsy shows a tumor mutational burden (TMB) of 13.0. Given these findings, would she be an appropriate candidate for Atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma (BLCA). Analysis of the tumor immune microenvironment from a ureter biopsy shows a tumor mutational burden (TMB) of 13.0. Given these findings, would she be an appropriate candidate for Atezolizumab therapy? Please review the patient’s transcriptomic data on the Compass platform to assess their suitability for immune checkpoint inhibitor therapy. Focus on biomarkers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular insights with the overall Compass score and the patient’s clinical history to construct a comprehensive immune profile that informs treatment response predictions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 16.0 based on a transcriptomic analysis of the tumor microenvironment from a kidney biopsy, is there evidence to suggest a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 16.0 based on a transcriptomic analysis of the tumor microenvironment from a kidney biopsy, is there evidence to suggest a favorable response to Atezolizumab therapy? Review the patient’s transcriptomic data on the Compass platform to determine their suitability for immune checkpoint inhibitor therapy. Specifically, evaluate biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immune profile that supports predictions of treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic profile of the tumor immune microenvironment, obtained from a kidney biopsy, revealed a tumor mutational burden (TMB) of 2.0. Can you evaluate how likely this patient is to respond to Atezolizumab therapy?","We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic profile of the tumor immune microenvironment, obtained from a kidney biopsy, revealed a tumor mutational burden (TMB) of 2.0. Can you evaluate how likely this patient is to respond to Atezolizumab therapy? Analyze the patient's transcriptomic data using the Compass platform to assess their eligibility for immune checkpoint inhibitor therapy. Specifically, examine biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular insights with the overall Compass score and the patient's clinical history to create a detailed immune profile that can help predict their treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"A White female patient with bladder urothelial carcinoma underwent a bladder biopsy, and transcriptomic profiling of her tumor immune microenvironment showed a tumor mutational burden (TMB) value reported as ""nan."" How should we interpret this TMB result in relation to her potential response to Atezolizumab therapy?","A White female patient with bladder urothelial carcinoma underwent a bladder biopsy, and transcriptomic profiling of her tumor immune microenvironment showed a tumor mutational burden (TMB) value reported as ""nan."" How should we interpret this TMB result in relation to her potential response to Atezolizumab therapy? Review the patient’s transcriptomic data using the Compass platform to determine their suitability for immune checkpoint inhibitor therapy. Focus on quantitative measures of macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation rates, and cytotoxic T-cell activity. Then, integrate these biomarker profiles with the overall Compass score and the patient’s clinical history to develop a comprehensive immune profile that guides predictions regarding their treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0 determined from a bladder biopsy transcriptomic profile, how likely is it that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0 determined from a bladder biopsy transcriptomic profile, how likely is it that he will respond to Atezolizumab therapy? Review the patient’s transcriptomic data on the Compass platform to evaluate their eligibility for immune checkpoint inhibitor therapy. Specifically, assess quantitative markers such as macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Then, combine these biomarker profiles with the overall Compass score and the patient’s clinical history to construct a detailed immune profile that will inform predictions about their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden of 20, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden of 20, what is the likelihood of a favorable response to Atezolizumab therapy? Access the patient's transcriptomic data on the Compass platform and evaluate their suitability for immune checkpoint inhibitor therapy. Specifically, review quantitative markers including macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Then integrate these biomarker results with the overall Compass score and the patient's clinical history to develop a comprehensive immune profile that will help predict their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"I have a Caucasian female patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The transcriptomic analysis of her tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 5.0. Based on this profile, can we expect a favorable response to Atezolizumab therapy?","I have a Caucasian female patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The transcriptomic analysis of her tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 5.0. Based on this profile, can we expect a favorable response to Atezolizumab therapy? Please retrieve the patient’s transcriptomic data from the Compass platform and assess their potential for immune checkpoint inhibitor therapy. Focus on evaluating quantitative markers such as macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Once these biomarkers are analyzed, combine the findings with the overall Compass score and the patient’s clinical history to create a detailed immune profile that will inform the prediction of their treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 38. Based on this finding, can we expect a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 38. Based on this finding, can we expect a favorable response to Atezolizumab therapy? Retrieve the patient's transcriptomic data from the Compass platform and evaluate their suitability for immune checkpoint inhibitor therapy. Specifically, examine quantitative biomarkers related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. After analyzing these individual markers, integrate your findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immune profile that supports predicting their response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"In a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment profile from a kidney biopsy reveals a tumor mutational burden of 6.0. Based on these findings, what is the likelihood that this patient will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment profile from a kidney biopsy reveals a tumor mutational burden of 6.0. Based on these findings, what is the likelihood that this patient will respond to atezolizumab therapy? Please access the patient’s transcriptomic data through the Compass platform and assess their suitability for immune checkpoint inhibitor therapy. In this evaluation, focus on quantifiable biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you have analyzed these individual parameters, combine your findings with the overall Compass score and the patient’s clinical history to create a detailed immune profile. This comprehensive profile should inform your prediction of the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis reveals a tumor mutational burden of 8.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis reveals a tumor mutational burden of 8.0, what is the likelihood of a favorable response to atezolizumab therapy? Retrieve the patient's transcriptomic data using the Compass platform and evaluate their eligibility for immune checkpoint inhibitor therapy. In your analysis, specifically quantify biomarkers that reflect macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After reviewing these biomarkers, integrate your results with the overall Compass score and the patient’s clinical history to construct a detailed immune profile. This profile will help predict the patient’s likely response to the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"In a white male patient with bladder urothelial carcinoma whose tumor transcriptomic profile shows a tumor mutational burden of 13.0 based on biopsy analysis, what is the likelihood that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose tumor transcriptomic profile shows a tumor mutational burden of 13.0 based on biopsy analysis, what is the likelihood that he will respond to Atezolizumab therapy? Access the patient's transcriptomic data through the Compass platform and assess their eligibility for immune checkpoint inhibitor therapy. In your evaluation, specifically measure biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once these biomarkers are quantified, combine your findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immune profile that will aid in predicting the likely therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"I have a Caucasian male patient diagnosed with Bladder Urothelial Carcinoma. Transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden of 5.0 mutations per megabase. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with Bladder Urothelial Carcinoma. Transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden of 5.0 mutations per megabase. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Retrieve the patient's transcriptomic data via the Compass platform and evaluate their suitability for immune checkpoint inhibitor therapy. In your assessment, quantify biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once these biomarkers are measured, integrate your findings with the overall Compass score and the patient’s clinical history to construct a detailed immune profile that can predict the likely therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"For a white female patient diagnosed with bladder urothelial carcinoma and a tumor mutational burden of 5.0 derived from the bladder biopsy transcriptomic profile, would you anticipate a favorable response to atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma and a tumor mutational burden of 5.0 derived from the bladder biopsy transcriptomic profile, would you anticipate a favorable response to atezolizumab therapy? Access the patient’s transcriptomic data through the Compass system and use it to determine their suitability for immune checkpoint inhibitor therapy. In your evaluation, carefully measure biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After quantifying these parameters, combine your results with the overall Compass score and the patient’s clinical history to develop a comprehensive immune profile that predicts their likely response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"A Caucasian female patient with bladder urothelial carcinoma had transcriptomic profiling of her tumor immune microenvironment from a kidney biopsy, which revealed a tumor mutational burden of 5.0. Based on these findings, what is the likelihood that she will respond to atezolizumab therapy?","A Caucasian female patient with bladder urothelial carcinoma had transcriptomic profiling of her tumor immune microenvironment from a kidney biopsy, which revealed a tumor mutational burden of 5.0. Based on these findings, what is the likelihood that she will respond to atezolizumab therapy? Please retrieve the patient's transcriptomic data from the Compass system to evaluate their suitability for immune checkpoint inhibitor therapy. Carefully quantify biomarkers that reflect macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these measurements with the overall Compass score and the patient's clinical history to create a comprehensive immune profile that predicts their potential response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"A white male patient with bladder urothelial carcinoma has a tumor transcriptomic profile from biopsy that reports a tumor mutational burden (TMB) value of ""nan."" How should we interpret this finding in terms of his potential response to atezolizumab therapy, and what additional data might be needed to guide treatment decisions?","A white male patient with bladder urothelial carcinoma has a tumor transcriptomic profile from biopsy that reports a tumor mutational burden (TMB) value of ""nan."" How should we interpret this finding in terms of his potential response to atezolizumab therapy, and what additional data might be needed to guide treatment decisions? Please access the patient’s transcriptomic data from the Compass system to determine their eligibility for immune checkpoint inhibitor therapy. In your analysis, quantify biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these findings with the overall Compass score and the patient's clinical history to build a comprehensive immune profile that can help predict their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"For a White female patient with a diagnosis of Bladder Urothelial Carcinoma (BLCA) whose tumor immune microenvironment profiling from a lymph node biopsy reveals a tumor mutation burden (TMB) of 12.0, what is the anticipated likelihood of response to Atezolizumab therapy?","For a White female patient with a diagnosis of Bladder Urothelial Carcinoma (BLCA) whose tumor immune microenvironment profiling from a lymph node biopsy reveals a tumor mutation burden (TMB) of 12.0, what is the anticipated likelihood of response to Atezolizumab therapy? Please review the patient's transcriptomic data from the Compass system to evaluate their suitability for immune checkpoint inhibitor therapy. Specifically, measure biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these findings with the overall Compass score and the patient's clinical history to develop a comprehensive immune profile that can help forecast their likely response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"I have an Asian male patient with bladder urothelial carcinoma whose tumor biopsy shows a tumor mutational burden of 1.0. Based on this transcriptomic profile of the tumor immune microenvironment, how likely is he to benefit from Atezolizumab therapy?","I have an Asian male patient with bladder urothelial carcinoma whose tumor biopsy shows a tumor mutational burden of 1.0. Based on this transcriptomic profile of the tumor immune microenvironment, how likely is he to benefit from Atezolizumab therapy? Review the patient’s transcriptomic data from the Compass system to determine if they are an appropriate candidate for immune checkpoint inhibitor therapy. In particular, assess biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these biomarker results with the overall Compass score and the patient's clinical history to create a detailed immune profile. This profile will help predict the patient’s potential response to the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"We have a white male patient diagnosed with bladder urothelial carcinoma who underwent transcriptomic profiling of his tumor immune microenvironment via bladder biopsy. His tumor mutational burden is 6.0 mutations per megabase. Based on this information, how might we evaluate his potential responsiveness to atezolizumab therapy?","We have a white male patient diagnosed with bladder urothelial carcinoma who underwent transcriptomic profiling of his tumor immune microenvironment via bladder biopsy. His tumor mutational burden is 6.0 mutations per megabase. Based on this information, how might we evaluate his potential responsiveness to atezolizumab therapy? Evaluate the patient's transcriptomic data from the Compass system to determine their suitability for immune checkpoint inhibitor therapy. Specifically, examine biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these findings with the overall Compass score and the patient’s clinical history to construct a detailed immune profile that can help predict their response to the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"For a patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile shows a tumor mutational burden (TMB) of 8.0, how likely is it that the patient will respond favorably to atezolizumab therapy?","For a patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile shows a tumor mutational burden (TMB) of 8.0, how likely is it that the patient will respond favorably to atezolizumab therapy? Review the patient's transcriptomic data from the Compass system to determine their eligibility for immune checkpoint inhibitor therapy. Focus on evaluating biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these biomarker findings with the overall Compass score and the patient's clinical history to develop a comprehensive immune profile that can help predict their response to the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"I have a white male patient with bladder urothelial carcinoma, and transcriptomic profiling from a kidney biopsy indicates a tumor mutational burden of 6.0. Based on this information, how likely is it that he will respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma, and transcriptomic profiling from a kidney biopsy indicates a tumor mutational burden of 6.0. Based on this information, how likely is it that he will respond to atezolizumab therapy? Please review the patient's transcriptomic data from the Compass system to assess their suitability for immune checkpoint inhibitor therapy. Specifically, evaluate biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these findings with the overall Compass score and the patient's clinical history to develop a comprehensive immune profile that can help predict their potential response to the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden (TMB) of 22.0. How should we interpret this finding in terms of predicting his response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden (TMB) of 22.0. How should we interpret this finding in terms of predicting his response to Atezolizumab therapy? Please review the patient's transcriptomic data from the Compass system, focusing on biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once these biomarkers have been evaluated, integrate the results with the overall Compass score and the patient's clinical history to develop a detailed immune profile that will help predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy revealed a tumor mutational burden (TMB) of 1.0. Based on these details, how likely is it that this patient will respond to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy revealed a tumor mutational burden (TMB) of 1.0. Based on these details, how likely is it that this patient will respond to atezolizumab therapy? Review the patient's transcriptomic data from the Compass system, paying close attention to biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After evaluating these markers, combine the results with the overall Compass score and the patient's clinical history to construct a comprehensive immune profile. This profile should inform your prediction of the patient’s likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of her tumor immune microenvironment from a ureter biopsy reported a tumor mutational burden (TMB) value as ""nan."" Can we determine her likelihood of responding to Atezolizumab therapy based on this information?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of her tumor immune microenvironment from a ureter biopsy reported a tumor mutational burden (TMB) value as ""nan."" Can we determine her likelihood of responding to Atezolizumab therapy based on this information? Please examine the patient’s transcriptomic profile from the Compass system, focusing on biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once you have evaluated these markers, integrate your findings with the overall Compass score and the patient’s clinical history to develop a detailed immune profile. Use this profile to assess and predict the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy reveals a tumor mutational burden of 2.0. Based on this profile, what is the likelihood of a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy reveals a tumor mutational burden of 2.0. Based on this profile, what is the likelihood of a favorable response to atezolizumab therapy? Review the patient’s transcriptomic data from the Compass system, paying special attention to biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate this analysis with the overall Compass score and the patient’s clinical history to construct a comprehensive immune profile. Then, use this profile to assess and predict the patient’s likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"Given a white male patient diagnosed with bladder urothelial carcinoma, whose transcriptomic analysis of the tumor immune microenvironment (from a bladder biopsy) reveals a tumor mutational burden of 11.0, how likely is he to respond to atezolizumab therapy?","Given a white male patient diagnosed with bladder urothelial carcinoma, whose transcriptomic analysis of the tumor immune microenvironment (from a bladder biopsy) reveals a tumor mutational burden of 11.0, how likely is he to respond to atezolizumab therapy? Analyze the patient’s transcriptomic report from the Compass system, focusing on biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine this molecular data with the overall Compass score and the patient’s clinical history to develop a detailed immune profile. Use this comprehensive profile to evaluate and predict the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"We have a white male patient with bladder urothelial carcinoma. Analysis of his tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 9.0. Based on this profile, what is his likely response to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma. Analysis of his tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 9.0. Based on this profile, what is his likely response to Atezolizumab therapy? Review the patient’s transcriptomic report from the Compass system with emphasis on markers that reflect macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical background to construct a detailed immune profile. Use this profile to assess and forecast the patient’s likelihood of benefiting from immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, a kidney biopsy was performed to obtain the transcriptomic profile of the tumor immune microenvironment, which revealed a TMB value reported as ""nan."" Based on these findings, how likely is this patient to respond to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, a kidney biopsy was performed to obtain the transcriptomic profile of the tumor immune microenvironment, which revealed a TMB value reported as ""nan."" Based on these findings, how likely is this patient to respond to Atezolizumab therapy? Please review the patient's transcriptomic report from the Compass system, paying particular attention to markers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the overall Compass score and relevant clinical information to develop a comprehensive immune profile. Use this detailed profile to evaluate and predict the patient's potential responsiveness to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 14.0 mutations/Mb. Based on these findings, is there evidence to suggest that this patient would respond favorably to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 14.0 mutations/Mb. Based on these findings, is there evidence to suggest that this patient would respond favorably to atezolizumab therapy? Please review the patient's transcriptomic report from the Compass system with attention to markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the overall Compass score and the patient’s clinical data to construct a comprehensive immunologic profile. Use this profile to assess and predict the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"A white male patient with bladder urothelial carcinoma has a tumor mutation burden (TMB) of 18 based on transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the likelihood that he would respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor mutation burden (TMB) of 18 based on transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the likelihood that he would respond to Atezolizumab therapy? Review the patient's transcriptomic report from the Compass system, focusing on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular results with the overall Compass score and the patient's clinical data to develop a comprehensive immunologic profile. Use this profile to evaluate and predict the patient's potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 13.0. Based on this information, how likely is the patient to respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 13.0. Based on this information, how likely is the patient to respond to atezolizumab therapy? Examine the patient’s transcriptomic report from the Compass system, particularly the indicators for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular findings with the overall Compass score and pertinent clinical data to create a detailed immunologic profile. Use this profile to assess and predict the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"For a Black or African American female patient with bladder urothelial carcinoma who has a tumor mutation burden of 8.0 based on a transcriptomic analysis of the tumor microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For a Black or African American female patient with bladder urothelial carcinoma who has a tumor mutation burden of 8.0 based on a transcriptomic analysis of the tumor microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Review the patient's transcriptomic results from the Compass system, focusing specifically on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular insights with the overall Compass score and relevant clinical information to develop a comprehensive immunologic profile. This profile will help you evaluate and predict the patient's likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"In a white female patient diagnosed with bladder urothelial carcinoma whose tumor biopsy transcriptomic analysis indicates a tumor mutational burden of 6.0, what is the likelihood of a favorable response to Atezolizumab therapy?","In a white female patient diagnosed with bladder urothelial carcinoma whose tumor biopsy transcriptomic analysis indicates a tumor mutational burden of 6.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please review the transcriptomic data from the Compass system for this patient, concentrating on markers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the overall Compass score and any pertinent clinical information to build a comprehensive immunologic profile. This profile will assist in assessing and predicting the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"A white male patient has been diagnosed with bladder urothelial carcinoma, and a transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy returned a TMB value of ""nan."" Could you help assess his potential response to atezolizumab therapy?","A white male patient has been diagnosed with bladder urothelial carcinoma, and a transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy returned a TMB value of ""nan."" Could you help assess his potential response to atezolizumab therapy? Please analyze the patient's transcriptomic data from the Compass system, focusing specifically on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Then, integrate these molecular findings with their overall Compass score and other relevant clinical details to create a detailed immunologic profile that can help us assess and predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"Given a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment analysis reveals a tumor mutational burden of 23.0, how likely is he to respond to Atezolizumab therapy based on current evidence?","Given a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment analysis reveals a tumor mutational burden of 23.0, how likely is he to respond to Atezolizumab therapy based on current evidence? Please review the patient's transcriptomic data from the Compass system, concentrating on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Following this, integrate these findings with the overall Compass score and other pertinent clinical information to build a comprehensive immunologic profile. This assessment will aid in predicting the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy showed a tumor mutational burden (TMB) reported as “nan.” Based on this finding, can you help determine her likelihood of responding to Atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy showed a tumor mutational burden (TMB) reported as “nan.” Based on this finding, can you help determine her likelihood of responding to Atezolizumab therapy? Please examine the patient's transcriptomic data from the Compass system, focusing on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, incorporate these findings with the overall Compass score and any other relevant clinical details to develop a complete immunologic profile. This evaluation will assist in predicting the patient’s likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"A  white male patient with bladder urothelial carcinoma has a lymph node biopsy indicating a tumor mutational burden (TMB) of 2.0. Based on this molecular profile, what is the likelihood that he will respond to Atezolizumab therapy?","A  white male patient with bladder urothelial carcinoma has a lymph node biopsy indicating a tumor mutational burden (TMB) of 2.0. Based on this molecular profile, what is the likelihood that he will respond to Atezolizumab therapy? Review the patient’s transcriptomic data from the Compass system with an emphasis on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, combine these findings with the overall Compass score and any additional pertinent clinical information to form a comprehensive immunologic profile. This evaluation will help us predict the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of his tumor's immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) value reported as “nan.” Based on this information, could you evaluate whether he is likely to respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of his tumor's immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) value reported as “nan.” Based on this information, could you evaluate whether he is likely to respond to Atezolizumab therapy? Please examine the patient’s transcriptomic profile obtained from the Compass system, focusing particularly on indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the overall Compass score and any other relevant clinical data to develop a detailed immunologic profile. This comprehensive assessment will assist in forecasting the patient’s likelihood of responding to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"In a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile shows a tumor mutational burden of 7.0, how likely is he to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile shows a tumor mutational burden of 7.0, how likely is he to respond to Atezolizumab therapy? Review the patient’s transcriptomic data from the Compass system with special attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular indicators with the overall Compass score and other pertinent clinical data to construct a detailed immunologic profile. This thorough evaluation will help estimate the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"An Asian male diagnosed with bladder urothelial carcinoma underwent a biopsy from which the transcriptomic profile of the tumor immune microenvironment was obtained, revealing a tumor mutational burden of 1.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","An Asian male diagnosed with bladder urothelial carcinoma underwent a biopsy from which the transcriptomic profile of the tumor immune microenvironment was obtained, revealing a tumor mutational burden of 1.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Examine the patient’s transcriptomic results from the Compass system, focusing on indicators such as macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Then, combine these findings with the overall Compass score and other relevant clinical data to create a comprehensive immunologic profile, which will inform our assessment of the patient’s likelihood of responding favorably to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,I have a white male patient diagnosed with bladder urothelial carcinoma. The tumor's immune microenvironment transcriptomic profile obtained from a ureter biopsy shows a tumor mutational burden (TMB) of 7.0. Could you please evaluate the likelihood of this patient responding to Atezolizumab therapy?,"I have a white male patient diagnosed with bladder urothelial carcinoma. The tumor's immune microenvironment transcriptomic profile obtained from a ureter biopsy shows a tumor mutational burden (TMB) of 7.0. Could you please evaluate the likelihood of this patient responding to Atezolizumab therapy? Review the patient's transcriptomic results from the Compass system, paying close attention to markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these findings with the overall Compass score and any other pertinent clinical data to develop a complete immunologic profile that will aid in assessing the patient's potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. His tumor transcriptomic profiling from a bladder biopsy revealed a tumor mutational burden of 5.0 mutations per megabase. Based on this TMB level, what is the likelihood of a favorable response to atezolizumab therapy?","We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. His tumor transcriptomic profiling from a bladder biopsy revealed a tumor mutational burden of 5.0 mutations per megabase. Based on this TMB level, what is the likelihood of a favorable response to atezolizumab therapy? Please review the patient’s transcriptomic data from the Compass system. Focus on the indicators for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, consider these findings alongside the overall Compass score and relevant clinical information to construct a comprehensive immunologic profile. This profile should be used to evaluate the patient’s likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 6.0. Based on these findings, could you assess his likelihood of responding to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 6.0. Based on these findings, could you assess his likelihood of responding to Atezolizumab therapy? Review the patient’s transcriptomic data from the Compass system, paying special attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these findings with the overall Compass score and other relevant clinical information to develop a detailed immunologic profile. This profile will help assess the patient’s expected response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment obtained from a lung biopsy shows a tumor mutational burden reported as ""nan."" Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment obtained from a lung biopsy shows a tumor mutational burden reported as ""nan."" Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Examine the patient’s transcriptomic dataset from the Compass system with emphasis on evaluating macrophage activation markers, interferon-gamma signaling, genomic integrity, cell proliferation rates, and the functionality of cytotoxic T-cells. Then, synthesize this molecular data with the overall Compass score and other clinical details to construct a comprehensive immunologic profile that will inform the anticipated response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutation burden (TMB) of 2.0. Based on these findings, how likely is this patient to respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutation burden (TMB) of 2.0. Based on these findings, how likely is this patient to respond to atezolizumab therapy? Review the patient's transcriptomic data from the Compass system, paying close attention to macrophage activation markers, interferon-gamma signaling, genomic integrity, cell proliferation indicators, and cytotoxic T-cell functionality. Combine these molecular findings with the overall Compass score and relevant clinical details to develop a comprehensive immunologic profile that can help predict the patient’s response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"A white male patient with bladder urothelial carcinoma (BLCA) has a tumor biopsy showing a transcriptomic profile of the immune microenvironment with a tumor mutational burden (TMB) of 44.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a tumor biopsy showing a transcriptomic profile of the immune microenvironment with a tumor mutational burden (TMB) of 44.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please evaluate the patient's transcriptomic data from the Compass system, focusing on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these molecular findings with the overall Compass score and pertinent clinical information to create a detailed immunologic profile that can help forecast the patient's response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"A White male patient diagnosed with Bladder Urothelial Carcinoma (BLCA) had a kidney biopsy performed to assess the transcriptomic profile of his tumor immune microenvironment, revealing a tumor mutational burden of 15.0 mutations per megabase. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A White male patient diagnosed with Bladder Urothelial Carcinoma (BLCA) had a kidney biopsy performed to assess the transcriptomic profile of his tumor immune microenvironment, revealing a tumor mutational burden of 15.0 mutations per megabase. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please review the patient's transcriptomic data from the Compass system, specifically examining markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular insights with the overall Compass score and relevant clinical details to construct a comprehensive immunologic profile that can help predict the patient's response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"I have a white male patient with bladder urothelial carcinoma whose lymph node biopsy reveals a transcriptomic profile with a tumor mutational burden of 17.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose lymph node biopsy reveals a transcriptomic profile with a tumor mutational burden of 17.0. Based on these findings, how likely is he to respond to Atezolizumab therapy? Review the patient’s transcriptomic profile from the Compass system, focusing on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the overall Compass score and relevant clinical details to develop a comprehensive immunologic profile that can help predict the patient’s response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"For a White male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment profiling from a kidney biopsy reveals a tumor mutational burden of 11.0, how likely is he to respond to atezolizumab therapy?","For a White male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment profiling from a kidney biopsy reveals a tumor mutational burden of 11.0, how likely is he to respond to atezolizumab therapy? Examine the patient's transcriptomic profile from the Compass system, paying particular attention to markers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Next, correlate these molecular insights with the overall Compass score and pertinent clinical details to develop a comprehensive immunologic profile that can guide predictions regarding the patient's response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy shows a transcriptomic profile of the tumor immune microenvironment with a reported TMB of ""nan,"" how might this impact his likelihood of responding to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy shows a transcriptomic profile of the tumor immune microenvironment with a reported TMB of ""nan,"" how might this impact his likelihood of responding to atezolizumab therapy? Review the patient's transcriptomic data from the Compass system, concentrating on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the overall Compass score and clinical details to construct a comprehensive immunologic profile that can help forecast the patient's response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,We have a Caucasian male patient with bladder urothelial carcinoma. The transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy indicates that the tumor mutational burden (TMB) is not available. Can you provide insights on whether this patient is likely to respond to atezolizumab therapy?,"We have a Caucasian male patient with bladder urothelial carcinoma. The transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy indicates that the tumor mutational burden (TMB) is not available. Can you provide insights on whether this patient is likely to respond to atezolizumab therapy? Examine the patient's Compass transcriptomic data with an emphasis on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, combine these molecular findings with the overall Compass score and pertinent clinical information to develop a comprehensive immunologic profile that will help predict the patient's response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 12.0 as determined from a bladder biopsy profiling the tumor immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 12.0 as determined from a bladder biopsy profiling the tumor immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy? Review the patient’s Compass transcriptomic data, focusing specifically on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the overall Compass score and relevant clinical details to construct a complete immunologic profile that can help forecast the patient's responsiveness to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,How likely is a positive response to Atezolizumab in a white male patient with bladder urothelial carcinoma (BLCA) whose tumor biopsy reveals a tumor mutational burden (TMB) of 6.0?,"How likely is a positive response to Atezolizumab in a white male patient with bladder urothelial carcinoma (BLCA) whose tumor biopsy reveals a tumor mutational burden (TMB) of 6.0? Examine the patient's Compass transcriptomic data with special attention to indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, correlate these molecular insights with the overall Compass score and the patient's clinical details to create a comprehensive immunologic profile that can help predict their response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) of 5.0. Based on this profile, how likely is the patient to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) of 5.0. Based on this profile, how likely is the patient to respond to Atezolizumab therapy? Review the patient’s Compass transcriptomic data, focusing on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunologic profile that can help predict their likelihood of responding to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"We have a white male patient diagnosed with bladder urothelial carcinoma (BLCA), and a nanobiopsy of his tumor immune microenvironment reveals a tumor mutational burden of 8.0 mutations per megabase. Based on these findings, what is his expected likelihood of responding to Atezolizumab therapy?","We have a white male patient diagnosed with bladder urothelial carcinoma (BLCA), and a nanobiopsy of his tumor immune microenvironment reveals a tumor mutational burden of 8.0 mutations per megabase. Based on these findings, what is his expected likelihood of responding to Atezolizumab therapy? Examine the patient’s Compass transcriptomic profile for biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the patient's overall Compass score and clinical history to develop a detailed immunologic profile that will help predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"We have a White male patient with a diagnosis of bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment, obtained from a bladder biopsy, indicates a tumor mutational burden (TMB) of 8.0. Based on this information, could you please evaluate his potential response to Atezolizumab therapy?","We have a White male patient with a diagnosis of bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment, obtained from a bladder biopsy, indicates a tumor mutational burden (TMB) of 8.0. Based on this information, could you please evaluate his potential response to Atezolizumab therapy? Review the patient's Compass transcriptomic data to identify biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Next, combine these molecular insights with the patient’s overall Compass score and clinical background to construct a comprehensive immunologic profile that will inform predictions regarding their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"For a male patient diagnosed with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile shows a tumor mutational burden (TMB) of 0.0, what is the likelihood that he will respond to Atezolizumab therapy?","For a male patient diagnosed with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile shows a tumor mutational burden (TMB) of 0.0, what is the likelihood that he will respond to Atezolizumab therapy? Please examine the patient's Compass transcriptomic profile to identify key biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the patient's overall Compass score and clinical history to develop a detailed immunologic profile. This profile will be used to help predict the patient's potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 5.0. Based on these findings, how would you assess his likelihood of responding to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 5.0. Based on these findings, how would you assess his likelihood of responding to atezolizumab therapy? Review the patient's Compass transcriptomic profile to extract key biomarkers associated with macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and the function of cytotoxic T cells. Then, correlate these molecular indicators with the overall Compass score and the patient's clinical history to construct a comprehensive immunologic profile, which will inform the assessment of their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"For a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment was characterized via transcriptomic profiling from a kidney biopsy, revealing a tumor mutation burden (TMB) of 6.0. Based on these findings, what is the likelihood of responding to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment was characterized via transcriptomic profiling from a kidney biopsy, revealing a tumor mutation burden (TMB) of 6.0. Based on these findings, what is the likelihood of responding to atezolizumab therapy? Examine the patient's Compass transcriptomic data to identify key biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Then, integrate these molecular findings with the overall Compass score and the patient’s clinical history to develop a detailed immunologic profile. This profile will support the evaluation of the patient's likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"I am managing a white female patient with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic profiling of her tumor’s immune microenvironment. The report indicates a tumor mutational burden (TMB) of 'nan'. Based on this information, what can be inferred about her likelihood of responding to Atezolizumab therapy?","I am managing a white female patient with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic profiling of her tumor’s immune microenvironment. The report indicates a tumor mutational burden (TMB) of 'nan'. Based on this information, what can be inferred about her likelihood of responding to Atezolizumab therapy? Review the patient's Compass transcriptomic data to identify critical biomarkers linked to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell function. Combine these molecular insights with the overall Compass score and the patient’s clinical history to construct a detailed immunologic profile. This profile will help assess the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a ureter biopsy indicates a tumor mutational burden of 59. Could you help evaluate his likelihood of responding to Atezolizumab therapy?,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a ureter biopsy indicates a tumor mutational burden of 59. Could you help evaluate his likelihood of responding to Atezolizumab therapy? Analyze the patient's Compass transcriptomic profile to identify key biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Integrate these molecular findings with the overall Compass score and the patient's clinical history to develop a comprehensive immunologic profile. This profile will be used to evaluate the patient's likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"For a white male patient with bladder urothelial carcinoma whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 13.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 13.0, what is the likelihood of a favorable response to Atezolizumab therapy? Review the patient's Compass transcriptomic report to pinpoint biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Combine these molecular insights with the overall Compass score and the patient’s clinical history to build a detailed immunologic profile. This profile will help assess the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"We have a patient diagnosed with bladder urothelial carcinoma. A ureteral biopsy of the tumor revealed a transcriptomic profile with a tumor mutational burden of 12.0. Based on these findings, what is your assessment of the likelihood of response to atezolizumab therapy?","We have a patient diagnosed with bladder urothelial carcinoma. A ureteral biopsy of the tumor revealed a transcriptomic profile with a tumor mutational burden of 12.0. Based on these findings, what is your assessment of the likelihood of response to atezolizumab therapy? Examine the patient's Compass transcriptomic report to identify biomarkers linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Integrate these molecular findings with the overall Compass score and the patient's clinical history to develop a detailed immunologic profile. This comprehensive profile will inform the assessment of the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A lymph node biopsy and subsequent transcriptomic analysis of the tumor immune microenvironment reveal a tumor mutational burden (TMB) of 4.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A lymph node biopsy and subsequent transcriptomic analysis of the tumor immune microenvironment reveal a tumor mutational burden (TMB) of 4.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Review the patient’s Compass transcriptomic report, focusing on biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Combine these molecular details with the overall Compass score and the patient’s clinical history to construct a thorough immunologic profile. This profile will be essential in evaluating the patient’s likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"I have a white male patient diagnosed with bladder urothelial carcinoma. His bladder biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutation burden (TMB) of 11.0. Based on these findings, is he likely to respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. His bladder biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutation burden (TMB) of 11.0. Based on these findings, is he likely to respond to Atezolizumab therapy? Review the patient’s Compass transcriptomic report, paying close attention to biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to construct a comprehensive immunologic profile. This profile will be critical for assessing the patient’s likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from a bladder biopsy indicates a tumor mutation burden (TMB) of 5.0. Based on this information, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from a bladder biopsy indicates a tumor mutation burden (TMB) of 5.0. Based on this information, what is the likelihood of a positive response to Atezolizumab therapy? Please examine the patient's Compass transcriptomic report focusing on biomarkers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Combine these molecular findings with the overall Compass score and the patient’s clinical history to develop a detailed immunologic profile. This work is crucial for evaluating the patient's potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"I have a White female patient diagnosed with bladder urothelial carcinoma. Her tumor immune microenvironment was profiled using a kidney biopsy, but the tumor mutational burden (TMB) was not determined. How should we interpret the likelihood of her responding to Atezolizumab therapy given this information?","I have a White female patient diagnosed with bladder urothelial carcinoma. Her tumor immune microenvironment was profiled using a kidney biopsy, but the tumor mutational burden (TMB) was not determined. How should we interpret the likelihood of her responding to Atezolizumab therapy given this information? Review the patient's Compass transcriptomic report with emphasis on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to construct a comprehensive immunologic profile, which will be essential for assessing the potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"For a White male patient diagnosed with Bladder Urothelial Carcinoma, whose tumor immune microenvironment was profiled from a ureter biopsy revealing a tumor mutation burden (TMB) of 5.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a White male patient diagnosed with Bladder Urothelial Carcinoma, whose tumor immune microenvironment was profiled from a ureter biopsy revealing a tumor mutation burden (TMB) of 5.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Examine the patient's Compass transcriptomic report, focusing on biomarkers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Combine these molecular details with the overall Compass score and the clinical history to develop a detailed immunologic profile, which is crucial for predicting the patient’s likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"For a Native Hawaiian or Other Pacific Islander patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic analysis shows a tumor mutational burden (TMB) of 19.0, how likely is it that the patient will respond to Atezolizumab therapy?","For a Native Hawaiian or Other Pacific Islander patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic analysis shows a tumor mutational burden (TMB) of 19.0, how likely is it that the patient will respond to Atezolizumab therapy? Review the patient’s Compass transcriptomic report with an emphasis on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to create a comprehensive immunologic profile that will help predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,I have a Caucasian male patient with bladder urothelial carcinoma whose transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy reported a TMB value of “nan.” How might this ambiguous TMB result affect his likelihood of responding to Atezolizumab therapy?,"I have a Caucasian male patient with bladder urothelial carcinoma whose transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy reported a TMB value of “nan.” How might this ambiguous TMB result affect his likelihood of responding to Atezolizumab therapy? Examine the patient’s Compass transcriptomic report, focusing specifically on indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Then, integrate these molecular data with the overall Compass score and the patient’s clinical history to develop a detailed immunologic profile that can help predict their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/563d62-ar-563d623.pkl. "
BLCA,,,,NR,"A white female patient with a diagnosis of bladder urothelial carcinoma underwent a bladder biopsy for transcriptomic profiling of her tumor immune microenvironment, and the report indicated that the tumor mutational burden (TMB) could not be determined. Could you assess her likelihood of responding to Atezolizumab therapy?","A white female patient with a diagnosis of bladder urothelial carcinoma underwent a bladder biopsy for transcriptomic profiling of her tumor immune microenvironment, and the report indicated that the tumor mutational burden (TMB) could not be determined. Could you assess her likelihood of responding to Atezolizumab therapy? Review the patient’s Compass transcriptomic report with particular attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Combine these molecular findings with the overall Compass score and the patient’s clinical history to construct a comprehensive immunologic profile. This profile should be used to assess and predict the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"In a white male patient diagnosed with bladder urothelial carcinoma, the tumor transcriptomic profile from a kidney biopsy indicates a tumor mutation burden (TMB) of 33.0. Based on this information, what is the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, the tumor transcriptomic profile from a kidney biopsy indicates a tumor mutation burden (TMB) of 33.0. Based on this information, what is the likelihood of a favorable response to Atezolizumab therapy? Review the patient’s Compass transcriptomics report by focusing on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Combine these molecular findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunologic profile, which will help assess and predict their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"A white male patient with bladder urothelial carcinoma has a tumor biopsy showing a tumor mutation burden (TMB) of 32.0. Based on these findings, what is the likelihood of a positive response to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor biopsy showing a tumor mutation burden (TMB) of 32.0. Based on these findings, what is the likelihood of a positive response to atezolizumab therapy? Please review the patient’s Compass transcriptomics report with a focus on markers for macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Then, integrate these molecular findings with the overall Compass score and the patient’s clinical history to construct a detailed immunologic profile. This profile will guide your assessment and help predict the patient’s likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"In a white male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis revealed a tumor mutational burden (TMB) of 2.0. Based on these findings, what is the likelihood that the patient will benefit from Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis revealed a tumor mutational burden (TMB) of 2.0. Based on these findings, what is the likelihood that the patient will benefit from Atezolizumab therapy? Review the patient's Compass transcriptomics report, paying special attention to markers associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Then, integrate these molecular findings with the overall Compass score and the patient's clinical history to develop a comprehensive immunologic profile. This profile will support your assessment and help predict the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"For a patient with bladder urothelial carcinoma whose tumor immune microenvironment profiling from a bladder biopsy reveals a tumor mutation burden (TMB) of 14.0, what is the likelihood of response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma whose tumor immune microenvironment profiling from a bladder biopsy reveals a tumor mutation burden (TMB) of 14.0, what is the likelihood of response to atezolizumab therapy? Please examine the patient's Compass transcriptomics report, focusing specifically on markers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Combine these molecular findings with the overall Compass score and the patient’s clinical history to create a detailed immunologic profile. This integrated profile will aid in assessing the patient’s status and in predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained from a nano biopsy and shows a TMB value of nan, can we predict his likelihood of responding to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained from a nano biopsy and shows a TMB value of nan, can we predict his likelihood of responding to Atezolizumab therapy? Review the patient's Compass transcriptomics report with particular attention to markers for macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Integrate these molecular findings with the overall Compass score and the patient's clinical history to develop a comprehensive immunologic profile. This detailed profile will assist in evaluating the patient's current state and in forecasting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"In a white male patient diagnosed with urothelial carcinoma of the bladder, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 9.0. Based on these findings, how likely is this patient to respond to atezolizumab therapy?","In a white male patient diagnosed with urothelial carcinoma of the bladder, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 9.0. Based on these findings, how likely is this patient to respond to atezolizumab therapy? Examine the patient's Compass transcriptomics report closely, focusing on markers that indicate macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Combine these molecular details with the overall Compass score and the patient's clinical history to construct a comprehensive immunologic profile. This profile will provide valuable insights into the patient's current condition and help predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"I have an Asian female patient with bladder urothelial carcinoma (BLCA). Her tumor immune microenvironment, analyzed via transcriptomic profiling from a ureter biopsy, exhibits a tumor mutation burden (TMB) of 12.0. Based on this information, what is the likelihood that she will respond favorably to Atezolizumab therapy?","I have an Asian female patient with bladder urothelial carcinoma (BLCA). Her tumor immune microenvironment, analyzed via transcriptomic profiling from a ureter biopsy, exhibits a tumor mutation burden (TMB) of 12.0. Based on this information, what is the likelihood that she will respond favorably to Atezolizumab therapy? Review the patient's Compass transcriptomics report with particular attention to markers of macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Combine these findings with the overall Compass score and the patient's clinical history to develop a detailed immunologic profile. This comprehensive profile will help us better understand the patient's current condition and anticipate their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a TMB value reported as ""nan."" How might this result affect our assessment of his potential response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a TMB value reported as ""nan."" How might this result affect our assessment of his potential response to atezolizumab therapy? Please review the patient's Compass transcriptomics report, paying close attention to the following areas: macrophage activation markers, interferon‐gamma signaling, genomic stability, indicators of cell proliferation, and signals related to cytotoxic T cell activity. Evaluate these results in conjunction with the overall Compass score and the patient's clinical history to construct a detailed immunologic profile. This profile will guide us in understanding the patient's current immunologic status and help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile shows a tumor mutational burden of 11.0, how might this TMB level influence his response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile shows a tumor mutational burden of 11.0, how might this TMB level influence his response to atezolizumab therapy? Please examine the patient's Compass transcriptomics report with a focus on macrophage activation markers, interferon‐gamma signaling, genomic stability, cell proliferation indices, and cytotoxic T cell activation signals. Integrate these findings with the overall Compass score and the patient's clinical background to develop a comprehensive immunologic profile. This profile will be instrumental in assessing the patient's current immune status and forecasting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"In a Caucasian male diagnosed with bladder urothelial carcinoma, transcriptomic profiling from a liver biopsy revealed a tumor mutational burden (TMB) of 10. Based on these findings, could you assess whether the patient is likely to respond favorably to atezolizumab therapy?","In a Caucasian male diagnosed with bladder urothelial carcinoma, transcriptomic profiling from a liver biopsy revealed a tumor mutational burden (TMB) of 10. Based on these findings, could you assess whether the patient is likely to respond favorably to atezolizumab therapy? Review the patient's Compass transcriptomics report with particular attention to markers of macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activation. Combine these findings with the overall Compass score and the patient’s clinical background to create a detailed immunologic profile. This profile is essential for assessing the patient’s current immune status and anticipating their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 12.0. Based on these findings, can we predict his likelihood of responding to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 12.0. Based on these findings, can we predict his likelihood of responding to atezolizumab therapy? Please review the patient’s Compass transcriptomics report, focusing on markers for macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activation. Then, integrate these findings with the overall Compass score and the patient's clinical history to construct a comprehensive immunologic profile. This profile is crucial for evaluating the patient’s current immune status and predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"In a patient with bladder urothelial carcinoma whose tumor immune microenvironment analysis from a bladder biopsy reveals a tumor mutational burden of 13.0, how likely is it that the patient will respond to Atezolizumab therapy based on current evidence?","In a patient with bladder urothelial carcinoma whose tumor immune microenvironment analysis from a bladder biopsy reveals a tumor mutational burden of 13.0, how likely is it that the patient will respond to Atezolizumab therapy based on current evidence? Review the patient’s Compass transcriptomics report by specifically assessing markers for macrophage activation, interferon‐gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell activity. Next, combine these findings with the overall Compass score and the patient’s clinical history to develop a detailed immunologic profile. This profile is essential for understanding the patient’s current immune state and for forecasting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"For a Caucasian male with bladder urothelial carcinoma, where transcriptomic profiling of a kidney biopsy reveals a tumor mutational burden (TMB) of 6.0, how likely is he to respond to Atezolizumab therapy?","For a Caucasian male with bladder urothelial carcinoma, where transcriptomic profiling of a kidney biopsy reveals a tumor mutational burden (TMB) of 6.0, how likely is he to respond to Atezolizumab therapy? Examine the patient’s Compass transcriptomics report, focusing on markers for macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell activity. Then, integrate these findings with the overall Compass score and the patient’s clinical history to construct a comprehensive immunologic profile. This profile is vital for assessing the patient’s current immune status and for predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"A white male patient with bladder urothelial carcinoma had a transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy that revealed a tumor mutational burden (TMB) of 21.0. Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma had a transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy that revealed a tumor mutational burden (TMB) of 21.0. Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy? Review the patient's Compass transcriptomics report with special attention to markers of macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell activity. Then, combine these data with the overall Compass score and the patient’s clinical history to develop a detailed immunologic profile. This comprehensive analysis is essential for evaluating the patient’s current immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"In a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomics show a tumor mutation burden of 14.0, what is the likelihood of response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomics show a tumor mutation burden of 14.0, what is the likelihood of response to Atezolizumab therapy? Please review the patient's Compass transcriptomics report, focusing specifically on markers of macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell activity. Then, integrate these findings with the overall Compass score and the patient’s clinical history to create a detailed immunologic profile. This comprehensive assessment is vital for evaluating the patient's current immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutation burden of 9.0, what is the likelihood that he will respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutation burden of 9.0, what is the likelihood that he will respond to atezolizumab therapy? Review the patient's Compass transcriptomics report with particular attention to markers of macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell activity. Combine these findings with the overall Compass score and the patient's clinical history to develop a detailed immunologic profile. This comprehensive evaluation is essential for assessing the patient’s current immune status and forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"For a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden (TMB) of 27 obtained from a bladder biopsy, how would you evaluate the likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden (TMB) of 27 obtained from a bladder biopsy, how would you evaluate the likelihood of a positive response to Atezolizumab therapy? Please thoroughly examine the patient’s Compass transcriptomics report, paying special attention to indicators of macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell activity. Then, integrate these molecular findings with the overall Compass score and the patient's clinical history to construct a detailed immunologic profile. This comprehensive assessment is crucial for determining the patient’s current immune status and for predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"We have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic profiling of her tumor immune microenvironment from a lymph node biopsy shows an indeterminate tumor mutational burden (TMB reported as 'nan'). Based on this profile, what is the likelihood that she would respond to Atezolizumab therapy?","We have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic profiling of her tumor immune microenvironment from a lymph node biopsy shows an indeterminate tumor mutational burden (TMB reported as 'nan'). Based on this profile, what is the likelihood that she would respond to Atezolizumab therapy? Carefully review the patient's Compass transcriptomics report, with specific attention to markers of macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the overall Compass score and the patient's clinical history to develop a comprehensive immunologic profile. This detailed evaluation is essential for understanding the patient’s current immune status and for predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"A white female patient with bladder urothelial carcinoma was assessed using transcriptomic profiling of tumor immune microenvironment from a kidney biopsy, which revealed a tumor mutational burden of 5.0. Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy?","A white female patient with bladder urothelial carcinoma was assessed using transcriptomic profiling of tumor immune microenvironment from a kidney biopsy, which revealed a tumor mutational burden of 5.0. Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy? Review the patient’s Compass transcriptomics report with a focus on markers for macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular findings with the overall Compass score and the patient's clinical history to construct a comprehensive immunologic profile. This thorough evaluation is crucial for accurately assessing the patient’s immune status and forecasting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) value of ""nan."" Based on these findings, is it feasible to predict whether the patient is likely to respond to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) value of ""nan."" Based on these findings, is it feasible to predict whether the patient is likely to respond to atezolizumab therapy? Review the patient's Compass transcriptomics report, paying close attention to indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these molecular insights with the overall Compass score and the patient's clinical history to develop a detailed immunologic profile. This comprehensive assessment is essential for accurately evaluating the patient’s immunological status and predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis reveals a tumor mutational burden (TMB) of 14.0, could you provide insights on the likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis reveals a tumor mutational burden (TMB) of 14.0, could you provide insights on the likelihood of a favorable response to Atezolizumab therapy? Please review the patient's Compass transcriptomics report, focusing on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular findings with the overall Compass score and the patient's clinical history to construct a detailed immunologic profile. This comprehensive evaluation is crucial for accurately assessing the patient's immunologic status and predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. Analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutation burden (TMB) of 4.0. Based on these findings, what is the likelihood that he would respond favorably to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. Analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutation burden (TMB) of 4.0. Based on these findings, what is the likelihood that he would respond favorably to Atezolizumab therapy? Review the patient's Compass transcriptomics report, paying special attention to markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular results with the overall Compass score and the patient's clinical history to build a detailed immunologic profile. This thorough evaluation is essential for accurately determining the patient’s immunologic status and forecasting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"I am evaluating a white male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 5.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","I am evaluating a white male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 5.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please review the patient's Compass transcriptomics report with a focus on markers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the overall Compass score and the patient's clinical history to construct a comprehensive immunologic profile. This detailed assessment is crucial for accurately determining the patient’s immunologic status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profiling shows a tumor mutational burden of 15 mutations per megabase, would you consider her a suitable candidate for atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profiling shows a tumor mutational burden of 15 mutations per megabase, would you consider her a suitable candidate for atezolizumab therapy? Please go over the patient's Compass transcriptomics report, paying special attention to indicators of macrophage activation, interferon-gamma pathways, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these molecular findings with the overall Compass score and the patient’s clinical background to develop a detailed immunologic profile. This analysis will help us accurately assess the patient's immune status and forecast their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"Can you evaluate whether a tumor mutational burden (TMB) of 13.0, as determined from the transcriptomic profile of a bladder biopsy in a white male patient diagnosed with bladder urothelial carcinoma, suggests a likely beneficial response to Atezolizumab therapy?","Can you evaluate whether a tumor mutational burden (TMB) of 13.0, as determined from the transcriptomic profile of a bladder biopsy in a white male patient diagnosed with bladder urothelial carcinoma, suggests a likely beneficial response to Atezolizumab therapy? Review the patient’s Compass transcriptomics report with a focus on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular findings with the overall Compass score and the patient’s clinical history to construct a comprehensive immunologic profile. This profile will be instrumental in evaluating the patient's immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"Given a Caucasian female patient with bladder urothelial carcinoma and a tumor mutational burden of 14.0 determined from transcriptomic analysis of a bladder biopsy, how likely is she to benefit from Atezolizumab therapy?","Given a Caucasian female patient with bladder urothelial carcinoma and a tumor mutational burden of 14.0 determined from transcriptomic analysis of a bladder biopsy, how likely is she to benefit from Atezolizumab therapy? Examine the patient’s Compass transcriptomics results, placing special emphasis on indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular data points with the overall Compass score and the patient's clinical history to develop a detailed immunologic profile. This comprehensive profile will help assess the patient’s immune function and forecast their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"In a Black/African American male patient diagnosed with bladder urothelial carcinoma, tumor transcriptomic profiling from a bladder biopsy revealed a tumor mutational burden (TMB) of 17. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In a Black/African American male patient diagnosed with bladder urothelial carcinoma, tumor transcriptomic profiling from a bladder biopsy revealed a tumor mutational burden (TMB) of 17. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Review the patient’s Compass transcriptomics data, paying close attention to markers related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to construct a comprehensive immunologic profile. This profile will be instrumental in evaluating the patient’s immune function and predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma, and his tumor transcriptomic profile from a bladder biopsy shows a tumor mutational burden of 7.0. Based on these findings, is he likely to respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma, and his tumor transcriptomic profile from a bladder biopsy shows a tumor mutational burden of 7.0. Based on these findings, is he likely to respond to Atezolizumab therapy? Examine the patient’s Compass transcriptomics data with special emphasis on markers for macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the overall Compass score and the patient’s clinical history to develop a detailed immunologic profile. This profile will aid in assessing the patient’s immune function and in predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 5.0 mutations/megabase. Based on these findings, what is the likelihood that this patient will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 5.0 mutations/megabase. Based on these findings, what is the likelihood that this patient will respond to Atezolizumab therapy? Review the patient's Compass transcriptomics data with a focus on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the overall Compass score and the patient's clinical history to construct a comprehensive immunologic profile. This profile will provide insights into the patient's immune function and help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"A white male patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile obtained from a lung biopsy, which shows a tumor mutational burden (TMB) of 20.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile obtained from a lung biopsy, which shows a tumor mutational burden (TMB) of 20.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Examine the patient’s transcriptomic data from the Compass analysis, specifically looking at markers related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Afterward, correlate these molecular features with the overall Compass score and the patient’s clinical history. This integrated approach will help develop a detailed immunologic profile, offering insights into the patient’s immune function and predicting how they might respond to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,A Caucasian male patient with bladder urothelial carcinoma has a tumor biopsy whose transcriptomic profiling reveals a tumor mutational burden (TMB) of 3.0. Does this TMB level suggest a likelihood of response to Atezolizumab therapy?,"A Caucasian male patient with bladder urothelial carcinoma has a tumor biopsy whose transcriptomic profiling reveals a tumor mutational burden (TMB) of 3.0. Does this TMB level suggest a likelihood of response to Atezolizumab therapy? Review the patient’s transcriptomic data from the Compass analysis, focusing on markers for macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Then, compare these molecular characteristics with the overall Compass score and the patient’s clinical history. This comprehensive review will help create a detailed immunologic profile, providing insights into the patient’s immune function and potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"I am managing a Black or African American male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment, obtained from a lymph node biopsy, reported a tumor mutational burden (TMB) value as ""nan"" (not available). Given these findings, what is the likelihood that this patient will respond to Atezolizumab therapy?","I am managing a Black or African American male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment, obtained from a lymph node biopsy, reported a tumor mutational burden (TMB) value as ""nan"" (not available). Given these findings, what is the likelihood that this patient will respond to Atezolizumab therapy? Review the patient's Compass transcriptomic data, concentrating on markers indicating macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Next, correlate these molecular findings with the overall Compass score and the patient's clinical history. This integrated evaluation will help you develop a thorough immunologic profile, which is essential for understanding the patient’s immune function and for predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who underwent a bladder biopsy for transcriptomic profiling of his tumor immune microenvironment; however, the test reported a tumor mutational burden (TMB) as undefined. Could you help assess whether this patient might respond favorably to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who underwent a bladder biopsy for transcriptomic profiling of his tumor immune microenvironment; however, the test reported a tumor mutational burden (TMB) as undefined. Could you help assess whether this patient might respond favorably to Atezolizumab therapy? Please review the patient's Compass transcriptomics report with particular attention to markers associated with macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the overall Compass score and the patient’s clinical history. This comprehensive analysis will assist in constructing a detailed immunologic profile, which is crucial for understanding the patient's immune function and for forecasting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"I have a white female patient diagnosed with bladder urothelial carcinoma. A nano-biopsy of her tumor immune microenvironment yielded transcriptomic data indicating a tumor mutational burden of 8.0. Based on these findings, could you advise on the likelihood of a favorable response to Atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. A nano-biopsy of her tumor immune microenvironment yielded transcriptomic data indicating a tumor mutational burden of 8.0. Based on these findings, could you advise on the likelihood of a favorable response to Atezolizumab therapy? Please examine the patient's Compass transcriptomics report, specifically focusing on markers that indicate macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the overall Compass score and the patient’s clinical history. This integrated approach will help build a detailed immunologic profile, which is essential for assessing the patient's immune function and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"In a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 6.0 based on transcriptomic analysis from a kidney biopsy, what is the likelihood of responding to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 6.0 based on transcriptomic analysis from a kidney biopsy, what is the likelihood of responding to Atezolizumab therapy? Review the patient's Compass transcriptomics report with special attention to markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular findings with the overall Compass score and the patient's clinical history to develop a comprehensive immunologic profile. This detailed profile is crucial for evaluating the patient's immune function and for predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, where biopsy transcriptomic profiling of the tumor immune microenvironment shows a tumor mutational burden of 17.0, what is the likelihood that he will respond to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, where biopsy transcriptomic profiling of the tumor immune microenvironment shows a tumor mutational burden of 17.0, what is the likelihood that he will respond to Atezolizumab therapy? Examine the patient's Compass transcriptomics report, paying close attention to indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the overall Compass score and the patient's clinical history to build a detailed immunologic profile. This comprehensive profile is essential for assessing immune function and forecasting the patient's potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"For a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden of 6.0 mutations/Mb. Based on this information, what is the likelihood that the patient will respond favorably to Atezolizumab treatment?","For a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden of 6.0 mutations/Mb. Based on this information, what is the likelihood that the patient will respond favorably to Atezolizumab treatment? Review the patient's Compass transcriptomics report, specifically focusing on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular insights with the overall Compass score and the patient’s clinical history to develop a comprehensive immunologic profile. This detailed profile will help assess the patient's immune function and predict their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"For a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy showed a tumor mutational burden (TMB) of 1.0. Based on these findings, how likely is it that he will benefit from Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy showed a tumor mutational burden (TMB) of 1.0. Based on these findings, how likely is it that he will benefit from Atezolizumab therapy? Examine the patient's Compass transcriptomics report with an emphasis on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to create a thorough immunologic profile. This comprehensive assessment will help determine the patient’s immune function and predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"In a Caucasian male patient with bladder urothelial carcinoma, the transcriptomic characterization of the tumor immune microenvironment obtained from a kidney biopsy indicates an undetermined tumor mutation burden. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, the transcriptomic characterization of the tumor immune microenvironment obtained from a kidney biopsy indicates an undetermined tumor mutation burden. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy? Review the patient's Compass transcriptomics report, emphasizing markers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the overall Compass score and the patient's clinical history to develop a detailed immunologic profile. This comprehensive evaluation will assist in assessing immune function and forecasting the patient’s response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"I have a White female patient with a diagnosis of Bladder Urothelial Carcinoma (BLCA) whose tumor transcriptomic profile, obtained from a kidney biopsy, indicates a tumor mutational burden (TMB) of 7.0. Based on this information, how likely is the patient to respond to Atezolizumab therapy?","I have a White female patient with a diagnosis of Bladder Urothelial Carcinoma (BLCA) whose tumor transcriptomic profile, obtained from a kidney biopsy, indicates a tumor mutational burden (TMB) of 7.0. Based on this information, how likely is the patient to respond to Atezolizumab therapy? Examine the patient's Compass transcriptomics report with particular attention to markers of macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular insights with the overall Compass score and the patient’s clinical history to create a detailed immunologic profile. This comprehensive assessment will help evaluate immune function and predict the patient’s likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"A white female patient with bladder urothelial carcinoma has undergone transcriptomic profiling of her tumor immune microenvironment from a bladder biopsy, revealing a tumor mutational burden of 21.0 mutations per megabase. Based on this information, can we determine if she is a likely candidate for a favorable response to Atezolizumab therapy?","A white female patient with bladder urothelial carcinoma has undergone transcriptomic profiling of her tumor immune microenvironment from a bladder biopsy, revealing a tumor mutational burden of 21.0 mutations per megabase. Based on this information, can we determine if she is a likely candidate for a favorable response to Atezolizumab therapy? Review the patient's Compass transcriptomics report, paying special attention to markers indicating macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunologic profile. This detailed profile will assist in assessing immune function and forecasting the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"A white male patient with bladder urothelial carcinoma underwent a ureteral biopsy, and the transcriptomic evaluation of the tumor immune microenvironment revealed a tumor mutational burden of 7.0. Based on these findings, can we predict whether he is likely to respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma underwent a ureteral biopsy, and the transcriptomic evaluation of the tumor immune microenvironment revealed a tumor mutational burden of 7.0. Based on these findings, can we predict whether he is likely to respond to Atezolizumab therapy? Review the patient’s Compass transcriptomics report with particular attention to markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular findings with the overall Compass score and the patient’s clinical history to construct a detailed immunologic profile. This profile will help assess the patient’s immune status and predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment, obtained from a lung biopsy, indicates a tumor mutational burden (TMB) of 6.0. Based on these findings, do you think he is likely to respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment, obtained from a lung biopsy, indicates a tumor mutational burden (TMB) of 6.0. Based on these findings, do you think he is likely to respond to Atezolizumab therapy? Review the patient's Compass transcriptomics report in detail, specifically noting markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with both the overall Compass score and the patient’s clinical history to develop a comprehensive immunologic profile. This profile will be used to evaluate the patient's immune status and to help predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"A white male patient with bladder urothelial carcinoma (BLCA) has undergone transcriptomic analysis of the tumor immune microenvironment via a kidney biopsy, which revealed a tumor mutation burden (TMB) of 6.0 mutations/megabase. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has undergone transcriptomic analysis of the tumor immune microenvironment via a kidney biopsy, which revealed a tumor mutation burden (TMB) of 6.0 mutations/megabase. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Please review the patient's Compass transcriptomics report thoroughly, paying close attention to markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, incorporate these molecular insights along with the overall Compass score and the patient's clinical history to create a detailed immunologic profile. This profile will serve to assess the patient's immune status and assist in predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a TMB value reported as ""nan."" Can we infer from this result whether he is likely to respond to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a TMB value reported as ""nan."" Can we infer from this result whether he is likely to respond to Atezolizumab therapy? Review the patient's Compass transcriptomics report carefully, focusing on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these molecular findings with the overall Compass score and the patient's clinical history to construct a comprehensive immunologic profile. This profile will be used to evaluate the patient's immune status and help predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden of 3.0, how would you assess the likelihood of a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden of 3.0, how would you assess the likelihood of a favorable response to atezolizumab therapy? Please review the patient's Compass transcriptomics report with particular attention to markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Use these molecular details along with the overall Compass score and the patient’s clinical history to develop an integrated immunologic profile. This profile should provide a clear picture of the patient’s immune status and assist in predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"For an Asian male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomics indicate a tumor mutational burden of 5.0 mutations per megabase, what is the likelihood of response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomics indicate a tumor mutational burden of 5.0 mutations per megabase, what is the likelihood of response to Atezolizumab therapy? Please carefully examine the patient's Compass transcriptomics report, giving special attention to biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Combine these specific molecular details with the overall Compass score and the patient's clinical history to develop a comprehensive immunologic profile. This profile should accurately reflect the patient’s immune status and help predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic profile of his tumor immune microenvironment from a bladder biopsy was performed, and the analysis yielded a tumor mutational burden (TMB) value of “nan.” Based on this information, can we determine whether he is likely to respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. A transcriptomic profile of his tumor immune microenvironment from a bladder biopsy was performed, and the analysis yielded a tumor mutational burden (TMB) value of “nan.” Based on this information, can we determine whether he is likely to respond to Atezolizumab therapy? Review the patient's Compass transcriptomics report with careful attention to biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these specific molecular findings with the Compass score and pertinent clinical history to construct a detailed immunologic profile. This profile should accurately represent the patient’s immune status and assist in predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"I have a white female patient with bladder urothelial carcinoma (BLCA). The tumor immune microenvironment transcriptomic profile from a ureteral biopsy indicates a tumor mutational burden (TMB) of 12.0. Based on these findings, how likely is she to respond to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma (BLCA). The tumor immune microenvironment transcriptomic profile from a ureteral biopsy indicates a tumor mutational burden (TMB) of 12.0. Based on these findings, how likely is she to respond to Atezolizumab therapy? Review the patient's Compass transcriptomics report, paying close attention to biomarkers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Combine these molecular findings with the Compass score and the patient's clinical history to develop a comprehensive immunologic profile. This profile should accurately depict the patient's immune status and help predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden (TMB) value reported as ""nan."" How should this finding inform our expectations regarding his potential response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden (TMB) value reported as ""nan."" How should this finding inform our expectations regarding his potential response to Atezolizumab therapy? Examine the patient's Compass transcriptomics report with a focus on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these molecular findings with the Compass score and the patient's clinical history to create a detailed immunologic profile. This profile should accurately reflect the patient's current immune status and assist in predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,A  white female patient diagnosed with bladder urothelial carcinoma has a tumor mutational burden (TMB) of 5.0 based on transcriptomic profiling of her biopsy. What is the likelihood of a clinically meaningful response to Atezolizumab in this context?,"A  white female patient diagnosed with bladder urothelial carcinoma has a tumor mutational burden (TMB) of 5.0 based on transcriptomic profiling of her biopsy. What is the likelihood of a clinically meaningful response to Atezolizumab in this context? Review the patient's Compass transcriptomics report, paying particular attention to biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular data with the Compass score and the patient's clinical history to develop a comprehensive immunologic profile. This profile should accurately depict the patient’s current immune status and help forecast the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 4.0 determined via transcriptomic analysis of a lymph node biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 4.0 determined via transcriptomic analysis of a lymph node biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Examine the patient’s Compass transcriptomics report with a focus on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these molecular findings with the Compass score and the patient's clinical history to build a detailed immunologic profile. This comprehensive profile should accurately represent the patient’s current immune status and help predict the likely effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"In a Caucasian male patient with bladder urothelial carcinoma, the tumor immune microenvironment profile from a bladder biopsy revealed a tumor mutational burden of 8.0. Based on this information, how likely is he to respond to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, the tumor immune microenvironment profile from a bladder biopsy revealed a tumor mutational burden of 8.0. Based on this information, how likely is he to respond to Atezolizumab therapy? Review the patient's Compass transcriptomics report by specifically assessing biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Combine these molecular data with the Compass score and the patient’s clinical history to create a detailed immunologic profile. This profile should accurately reflect the patient's current immune status and inform the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"A white male patient diagnosed with bladder urothelial carcinoma underwent transcriptomic profiling of the tumor immune microenvironment via a bladder biopsy, which reported a tumor mutational burden (TMB) result as ""nan."" How should we interpret this finding in relation to the potential response to Atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma underwent transcriptomic profiling of the tumor immune microenvironment via a bladder biopsy, which reported a tumor mutational burden (TMB) result as ""nan."" How should we interpret this finding in relation to the potential response to Atezolizumab therapy? Examine the patient's Compass transcriptomics report with particular attention to biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these molecular findings with the patient's Compass score and clinical history to develop a comprehensive immunologic profile that accurately represents their current immune status and informs the likely effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"For a Black or African American male patient with bladder urothelial carcinoma and a tumor mutational burden of 1.0 determined via transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, how likely is it that he will respond to atezolizumab therapy?","For a Black or African American male patient with bladder urothelial carcinoma and a tumor mutational burden of 1.0 determined via transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, how likely is it that he will respond to atezolizumab therapy? Review the patient’s Compass transcriptomics report with a focus on biomarkers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular data with the patient’s Compass score and clinical history to create a detailed immunologic profile, which will help evaluate their current immune status and predict the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"For an Asian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a kidney biopsy shows a tumor mutation burden of 11.0, what is the anticipated response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a kidney biopsy shows a tumor mutation burden of 11.0, what is the anticipated response to Atezolizumab therapy? Review the patient's Compass transcriptomic report concentrating on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these findings with the patient's Compass score and clinical history to develop a comprehensive immunologic profile. This profile will help assess the patient’s current immune status and predict their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy showed a tumor mutational burden of 8.0. Based on these findings, is it likely that he will respond favorably to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy showed a tumor mutational burden of 8.0. Based on these findings, is it likely that he will respond favorably to atezolizumab therapy? Please review the patient's Compass transcriptomic report, paying particular attention to biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After that, integrate these findings with the patient's Compass score and clinical history to compile a detailed immunologic profile. This comprehensive profile will assist in evaluating the patient's current immune status and in predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma. The transcriptomic profile from a bladder biopsy shows a tumor mutational burden (TMB) of 7.0. Based on these findings, what is the likelihood that this patient will respond to atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. The transcriptomic profile from a bladder biopsy shows a tumor mutational burden (TMB) of 7.0. Based on these findings, what is the likelihood that this patient will respond to atezolizumab therapy? Review the patient's Compass transcriptomic report, focusing on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these findings with the patient's Compass score and clinical history to develop a comprehensive immunologic profile. This profile will help us assess the patient's immune status and predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"I have a white male patient with bladder urothelial carcinoma whose recent biopsy of the tumor immune microenvironment yielded a transcriptomic profile indicating a tumor mutational burden (TMB) value of ""nan."" Could you help determine if this patient is likely to benefit from Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose recent biopsy of the tumor immune microenvironment yielded a transcriptomic profile indicating a tumor mutational burden (TMB) value of ""nan."" Could you help determine if this patient is likely to benefit from Atezolizumab therapy? Review the patient's Compass transcriptomic report and specifically assess biomarkers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these data with the patient's Compass score and clinical history to construct a detailed immunologic profile. This comprehensive evaluation will enable us to better understand the patient's immune function and estimate their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"For a white male patient with bladder urothelial carcinoma whose biopsy shows a tumor mutational burden of 5.0, how likely is it that he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose biopsy shows a tumor mutational burden of 5.0, how likely is it that he will respond to Atezolizumab therapy? Please review the patient's Compass transcriptomic report with particular attention to biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Use this information, along with the patient's Compass score and clinical history, to develop a comprehensive immunologic profile. This will help us better understand the patient's immune function and predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"A white male patient with bladder urothelial carcinoma has undergone a lung biopsy for transcriptomic profiling of his tumor immune microenvironment, revealing a tumor mutational burden of 8.0. Based on these findings, do you consider him a likely candidate for Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has undergone a lung biopsy for transcriptomic profiling of his tumor immune microenvironment, revealing a tumor mutational burden of 8.0. Based on these findings, do you consider him a likely candidate for Atezolizumab therapy? Please examine the patient's Compass transcriptomic report, focusing on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these findings with the patient’s Compass score and clinical history to compile a detailed immunologic profile. This profile will aid in understanding the patient's immune function and anticipating their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"In a Caucasian female patient with bladder urothelial carcinoma, a bladder biopsy revealed a tumor mutation burden (TMB) of 14.0. Based on this transcriptomic profile of the tumor immune microenvironment, how likely is it that she will respond to atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, a bladder biopsy revealed a tumor mutation burden (TMB) of 14.0. Based on this transcriptomic profile of the tumor immune microenvironment, how likely is it that she will respond to atezolizumab therapy? Review the patient’s Compass transcriptomic report, paying close attention to biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these observations with the patient's Compass score and clinical history to create a comprehensive immunologic profile. This profile will help assess the patient’s immune function and inform predictions regarding their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"For a white male patient with bladder urothelial carcinoma, whose transcriptomic analysis of the tumor immune microenvironment indicates a tumor mutational burden (TMB) of 13.0, is there evidence to suggest that Atezolizumab therapy would likely be effective?","For a white male patient with bladder urothelial carcinoma, whose transcriptomic analysis of the tumor immune microenvironment indicates a tumor mutational burden (TMB) of 13.0, is there evidence to suggest that Atezolizumab therapy would likely be effective? Examine the patient’s Compass transcriptomic report, focusing on biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these findings with the Compass score and the patient’s clinical history to develop a detailed immunologic profile. This profile will be essential in evaluating the patient’s immune function and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"For an Asian male patient with bladder urothelial carcinoma whose tumor biopsy transcriptomics indicate a tumor mutation burden of 14.0, would you anticipate a favorable response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma whose tumor biopsy transcriptomics indicate a tumor mutation burden of 14.0, would you anticipate a favorable response to Atezolizumab therapy? Review the patient’s Compass transcriptomic report with an emphasis on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, combine these findings with the Compass score and the patient’s clinical history to construct a comprehensive immunologic profile. This profile is critical for evaluating the patient's immune status and forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled from a kidney biopsy, revealing a tumor mutation burden (TMB) of 7.0. Based on these findings, could you evaluate the likelihood of a positive response to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled from a kidney biopsy, revealing a tumor mutation burden (TMB) of 7.0. Based on these findings, could you evaluate the likelihood of a positive response to Atezolizumab therapy? Please review the patient’s Compass transcriptomic report, focusing specifically on biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these biomarker findings with the Compass score and the patient’s clinical history to develop a comprehensive immunologic profile. This profile is essential for assessing the patient’s immune status and predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"In a Caucasian male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling from a bladder biopsy revealed a tumor mutation burden of 6.0. Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a Caucasian male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling from a bladder biopsy revealed a tumor mutation burden of 6.0. Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy? Review the patient's Compass transcriptomic report, concentrating on biomarkers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these findings with the Compass score and relevant clinical history to create a thorough immunologic profile. This profile will assist in evaluating the patient’s immune status and estimating their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"A Caucasian male patient with bladder urothelial carcinoma underwent a kidney biopsy, and his tumor microenvironment transcriptomic profile indicates a tumor mutational burden of 6.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma underwent a kidney biopsy, and his tumor microenvironment transcriptomic profile indicates a tumor mutational burden of 6.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy? Please review the patient's Compass transcriptomic analysis with a focus on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once these results are obtained, integrate them with the patient’s Compass score and relevant clinical history to develop a comprehensive immunologic profile. This profile will inform our evaluation of the patient’s immune status and help predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"I am managing a white male patient with bladder urothelial carcinoma, and his bladder biopsy transcriptomic analysis shows a tumor mutational burden of 5.0. Could you provide an assessment of his likelihood of responding to atezolizumab therapy?","I am managing a white male patient with bladder urothelial carcinoma, and his bladder biopsy transcriptomic analysis shows a tumor mutational burden of 5.0. Could you provide an assessment of his likelihood of responding to atezolizumab therapy? Please examine the patient’s Compass transcriptomic data with particular attention to biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After obtaining these results, combine them with the patient’s overall Compass score and pertinent clinical history to construct a detailed immunologic profile. This comprehensive profile will guide our assessment of the patient’s immune function and help forecast their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"For a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic analysis from a bladder biopsy shows a tumor mutational burden (TMB) of 49.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic analysis from a bladder biopsy shows a tumor mutational burden (TMB) of 49.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Review the patient’s Compass transcriptomic data, focusing on biomarkers that signal macrophage activation, interferon-gamma activity, genomic stability, cell proliferation, and cytotoxic T-cell function. Once you have these findings, integrate them with the patient’s overall Compass score and relevant clinical history to construct a comprehensive immunologic profile. This detailed profile will inform our evaluation of the patient’s immune status and help predict their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"A Caucasian male patient with bladder urothelial carcinoma has a tumor mutation burden of 12.0 based on transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy. Based on this information, is he likely to benefit from Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a tumor mutation burden of 12.0 based on transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy. Based on this information, is he likely to benefit from Atezolizumab therapy? Examine the patient's Compass transcriptomic data, paying particular attention to biomarkers that indicate macrophage activation, interferon-gamma activity, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these findings with the overall Compass score and the patient's clinical history to develop a comprehensive immunologic profile. This profile will be instrumental in assessing the patient's immune status and predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, the transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy did not yield a measurable tumor mutational burden (TMB). Based on this profile, what insights can we draw regarding his likely response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, the transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy did not yield a measurable tumor mutational burden (TMB). Based on this profile, what insights can we draw regarding his likely response to Atezolizumab therapy? Review the patient's Compass transcriptomic data with a focus on biomarkers related to macrophage activation, interferon-gamma activity, genomic integrity, cell proliferation, and cytotoxic T-cell function. Then, integrate these biomarker results with the overall Compass score and the patient's clinical history to construct a detailed immunologic profile. This profile will help assess the patient's immune status and guide predictions regarding their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"I am managing a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor microenvironment from a bladder biopsy showed a tumor mutational burden (TMB) of 5. Based on this profile, how likely is he to benefit from atezolizumab therapy?","I am managing a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor microenvironment from a bladder biopsy showed a tumor mutational burden (TMB) of 5. Based on this profile, how likely is he to benefit from atezolizumab therapy? Examine the patient's Compass transcriptomic results, paying particular attention to biomarkers linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these findings with the overall Compass score and the patient's clinical history to develop a comprehensive immunological profile. This evaluation will help determine the patient's current immune status and inform predictions regarding their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"For a Black/African American male patient diagnosed with bladder urothelial carcinoma, the tumor microenvironment transcriptomic profiling from a kidney biopsy indicates a tumor mutational burden of 11.0. Based on current evidence, how might this TMB level influence his likelihood of responding to Atezolizumab therapy?","For a Black/African American male patient diagnosed with bladder urothelial carcinoma, the tumor microenvironment transcriptomic profiling from a kidney biopsy indicates a tumor mutational burden of 11.0. Based on current evidence, how might this TMB level influence his likelihood of responding to Atezolizumab therapy? Review the patient’s Compass transcriptomic data by specifically evaluating biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these findings with the overall Compass score and the patient’s clinical history to construct a comprehensive immunological profile. This detailed evaluation will assist in assessing the patient’s current immune status and in predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"A white male patient diagnosed with bladder urothelial carcinoma has undergone transcriptomic profiling of his tumor immune microenvironment via a bladder biopsy, which reported a tumor mutational burden (TMB) as nan. Based on these findings, how likely is he to respond to atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma has undergone transcriptomic profiling of his tumor immune microenvironment via a bladder biopsy, which reported a tumor mutational burden (TMB) as nan. Based on these findings, how likely is he to respond to atezolizumab therapy? Examine the patient’s Compass transcriptomic data with an emphasis on biomarkers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This assessment will help determine the patient’s current immune status and predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"We have a white male patient with bladder urothelial carcinoma who underwent a ureter biopsy for tumor immune microenvironment analysis. The transcriptomic profile reported a tumor mutational burden (TMB) value of ""nan."" How should we interpret this result in terms of predicting his likely response to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma who underwent a ureter biopsy for tumor immune microenvironment analysis. The transcriptomic profile reported a tumor mutational burden (TMB) value of ""nan."" How should we interpret this result in terms of predicting his likely response to Atezolizumab therapy? Review the patient’s Compass transcriptomic profile, focusing on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to construct a detailed immunological profile. This profile will provide insights into the patient’s current immune status and help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma, and a transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 17. Could you please assess his likelihood of responding to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma, and a transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 17. Could you please assess his likelihood of responding to Atezolizumab therapy? Examine the patient’s Compass transcriptomic profile, specifically noting biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular insights with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This profile will offer valuable information on the patient's current immune status and assist in forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy showed a tumor mutational burden of 22.0. Based on this information, how likely is he to benefit from Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy showed a tumor mutational burden of 22.0. Based on this information, how likely is he to benefit from Atezolizumab therapy? Review the patient’s Compass transcriptomic analysis, paying particular attention to biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to assemble a detailed immunological profile. This comprehensive profile will provide crucial insights into the patient’s current immune status and help predict their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"A white male patient with bladder urothelial carcinoma (BLCA) has undergone a bladder biopsy with transcriptomic profiling of the tumor immune microenvironment, which reported a tumor mutational burden (TMB) as NaN. Based on this information, could you provide an assessment of the patient's likely response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has undergone a bladder biopsy with transcriptomic profiling of the tumor immune microenvironment, which reported a tumor mutational burden (TMB) as NaN. Based on this information, could you provide an assessment of the patient's likely response to Atezolizumab therapy? Examine the patient's Compass transcriptomic results, focusing on biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Correlate these molecular markers with the overall Compass score and the patient's clinical history to construct a detailed immunological profile. This profile will offer essential insights into the patient’s immune status and assist in forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"I am managing a patient with bladder urothelial carcinoma who underwent a kidney biopsy. The transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutation burden of 18.0. Based on these findings, how likely is it that the patient will respond favorably to Atezolizumab therapy?","I am managing a patient with bladder urothelial carcinoma who underwent a kidney biopsy. The transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutation burden of 18.0. Based on these findings, how likely is it that the patient will respond favorably to Atezolizumab therapy? Review the patient's Compass transcriptomic report by focusing on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Compare these molecular markers with the overall Compass score and the patient's clinical history to develop a comprehensive immunological profile. This profile will provide valuable insights into the patient’s immune status and aid in predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, obtained via a kidney biopsy, reveals a tumor mutation burden of 5.0. Based on this information, would you consider him a likely candidate for Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, obtained via a kidney biopsy, reveals a tumor mutation burden of 5.0. Based on this information, would you consider him a likely candidate for Atezolizumab therapy? Examine the patient's Compass transcriptomic report with a focus on biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Cross-reference these molecular markers with the overall Compass score and the patient's clinical history to formulate a detailed immunological profile. This profile will help evaluate the patient’s immune status and assist in forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"For a white male patient with bladder urothelial carcinoma whose tumor transcriptomic profiling from a bladder biopsy shows a tumor mutational burden of 4.0, how likely is it that he would respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose tumor transcriptomic profiling from a bladder biopsy shows a tumor mutational burden of 4.0, how likely is it that he would respond to atezolizumab therapy? Review the patient's Compass transcriptomic report, concentrating on biomarkers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Correlate these molecular indicators with the overall Compass score and the patient’s clinical history to develop an integrated immunological profile. This comprehensive profile will inform an evaluation of the patient’s immune status and help predict their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"A white male patient with bladder urothelial carcinoma has undergone transcriptomic profiling of his tumor immune microenvironment from a kidney biopsy, which revealed a tumor mutational burden of 5.0. Based on this information, is it likely that he will respond favorably to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has undergone transcriptomic profiling of his tumor immune microenvironment from a kidney biopsy, which revealed a tumor mutational burden of 5.0. Based on this information, is it likely that he will respond favorably to Atezolizumab therapy? Examine the patient’s Compass transcriptomic report with a focus on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Relate these molecular findings to the overall Compass score and the patient’s clinical history to construct a detailed immunological profile. This profile will be used to assess the patient's immune status and predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"For a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment, evaluated via kidney biopsy, exhibits a TMB of 12.0, what is the expected response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment, evaluated via kidney biopsy, exhibits a TMB of 12.0, what is the expected response to Atezolizumab therapy? Review the patient’s Compass transcriptomic report with special attention to biomarkers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This profile will help assess the patient’s immune status and predict their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"A white male patient with bladder urothelial carcinoma (BLCA) underwent a liver biopsy for transcriptomic profiling of the tumor immune microenvironment, which reported a tumor mutation burden (TMB) value of ""nan."" Based on this information, what is the likelihood that this patient would benefit from Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) underwent a liver biopsy for transcriptomic profiling of the tumor immune microenvironment, which reported a tumor mutation burden (TMB) value of ""nan."" Based on this information, what is the likelihood that this patient would benefit from Atezolizumab therapy? Please examine the patient’s Compass transcriptomic report, paying particular attention to biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular markers with the overall Compass score and the patient’s clinical history to construct a detailed immunological profile. This profile will be used to evaluate the patient’s immune status and help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"In a white female patient with bladder urothelial carcinoma, a kidney biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden reported as nan. Based on this information, can we predict whether she is likely to respond to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, a kidney biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden reported as nan. Based on this information, can we predict whether she is likely to respond to Atezolizumab therapy? Please review the patient's Compass transcriptomic report, focusing on biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular data with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This profile will assist in assessing the patient’s immune status and predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"A white male patient with bladder urothelial carcinoma has a tumor mutational burden (TMB) of 10.0 as determined by transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy. Based on this profile, what is the likelihood of a favorable response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor mutational burden (TMB) of 10.0 as determined by transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy. Based on this profile, what is the likelihood of a favorable response to Atezolizumab therapy? Review the patient's Compass transcriptomic report, paying special attention to biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular insights with the overall Compass score and the patient's clinical history to construct a detailed immunological profile. This profile will be used to evaluate the patient's immune status and to help forecast their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"For a Caucasian female patient with bladder urothelial carcinoma, whose transcriptomic analysis from a bladder biopsy shows a tumor mutational burden of 6.0, what is the likelihood that she will respond favorably to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, whose transcriptomic analysis from a bladder biopsy shows a tumor mutational burden of 6.0, what is the likelihood that she will respond favorably to Atezolizumab therapy? Examine the patient's Compass transcriptomic report, focusing on biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the overall Compass score and the patient's clinical history to develop a comprehensive immunological profile. This profile will help in assessing the patient’s immune status and forecasting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"For a Caucasian female patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile from a bladder biopsy reports an unavailable tumor mutational burden (TMB), how might this impact her likelihood of responding to atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile from a bladder biopsy reports an unavailable tumor mutational burden (TMB), how might this impact her likelihood of responding to atezolizumab therapy? Review the patient's Compass transcriptomic report with particular emphasis on biomarkers that reflect macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, combine these molecular insights with the overall Compass score and the patient's clinical history to construct a detailed immunological profile. This profile will aid in evaluating the patient's immune status and in predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"A white female patient with a confirmed diagnosis of bladder urothelial carcinoma underwent a bladder biopsy, and the transcriptomic analysis of her tumor immune microenvironment revealed a tumor mutational burden (TMB) of 15. Could you evaluate the likelihood of her responding to atezolizumab therapy based on these findings?","A white female patient with a confirmed diagnosis of bladder urothelial carcinoma underwent a bladder biopsy, and the transcriptomic analysis of her tumor immune microenvironment revealed a tumor mutational burden (TMB) of 15. Could you evaluate the likelihood of her responding to atezolizumab therapy based on these findings? Please review the patient’s Compass transcriptomic report, paying close attention to biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular data with the overall Compass score and the patient's clinical history to develop a comprehensive immunological profile designed to assess the patient's immune status and forecast their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a lymph node biopsy has revealed a tumor mutational burden (TMB) of 8. Based on this information, how likely is he to respond to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a lymph node biopsy has revealed a tumor mutational burden (TMB) of 8. Based on this information, how likely is he to respond to atezolizumab therapy? Review the patient's Compass transcriptomic report, focusing specifically on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these findings with the overall Compass score and the patient's clinical history to create a detailed immunological profile, which will help assess the patient's current immune status and predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"A Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 6.0 based on transcriptomic profiling from a bladder biopsy. Based on these findings, how likely is he to respond to Atezolizumab therapy?","A Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 6.0 based on transcriptomic profiling from a bladder biopsy. Based on these findings, how likely is he to respond to Atezolizumab therapy? Examine the patient’s Compass transcriptomic report with an emphasis on the markers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the overall Compass score and the patient’s clinical history to compile a comprehensive immunological profile. This profile will be used to evaluate the patient’s current immune condition and to help forecast their potential response to immune checkpoint inhibitor treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"For a white male patient with bladder urothelial carcinoma and a biopsy transcriptomic profile indicating a tumor mutational burden of 19, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma and a biopsy transcriptomic profile indicating a tumor mutational burden of 19, what is the likelihood of a favorable response to Atezolizumab therapy? Review the patient’s Compass transcriptomic report, specifically evaluating gene markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular data with the overall Compass score and the patient’s clinical history to develop a detailed immunological profile. This comprehensive evaluation will assist in assessing the current immune status and predicting the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis from a separate biopsy indicates a tumor mutational burden (TMB) of 12. Based on this information, what is the likelihood that he will respond to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis from a separate biopsy indicates a tumor mutational burden (TMB) of 12. Based on this information, what is the likelihood that he will respond to atezolizumab therapy? Examine the patient’s Compass transcriptomic report with a focus on gene markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to create a detailed immunological profile. This comprehensive evaluation will help determine the patient’s current immune status and forecast their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"We have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment was performed using a kidney biopsy, and the tumor mutational burden was reported as 'nan'. Based on these findings, could you evaluate the likelihood of response to Atezolizumab therapy?","We have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment was performed using a kidney biopsy, and the tumor mutational burden was reported as 'nan'. Based on these findings, could you evaluate the likelihood of response to Atezolizumab therapy? Review the patient’s Compass transcriptomic report by focusing on gene markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular findings with the overall Compass score and the patient’s clinical history to build a thorough immunological profile. This integrated assessment will help establish the patient’s current immune status and predict their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 3.0, as determined by transcriptomic analysis of the tumor's immune microenvironment from a bladder biopsy. Based on this information, how likely is the patient to respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 3.0, as determined by transcriptomic analysis of the tumor's immune microenvironment from a bladder biopsy. Based on this information, how likely is the patient to respond to Atezolizumab therapy? Examine the patient’s Compass transcriptomic report with particular attention to gene markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the overall Compass score and the patient’s clinical history to develop a detailed immunological profile. This comprehensive evaluation will assist in determining the patient’s current immune status and in predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis from a lymph node biopsy reveals a tumor mutation burden of 18.0. Based on this molecular profile, how likely is the patient to respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis from a lymph node biopsy reveals a tumor mutation burden of 18.0. Based on this molecular profile, how likely is the patient to respond to atezolizumab therapy? Review the patient’s Compass transcriptomic report, focusing on specific gene markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, correlate these molecular insights with the overall Compass score and the patient’s clinical background to create a detailed immunological profile. This thorough analysis will help assess the patient’s current immune status and forecast their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 15. Could you assess the potential response to atezolizumab therapy in this case?,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 15. Could you assess the potential response to atezolizumab therapy in this case? Please review the patient's Compass transcriptomic report with a focus on gene markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular insights with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This approach will aid in evaluating the patient’s current immune status and predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"In a Caucasian male diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy indicated a TMB of ""nan."" How should we interpret this finding in the context of predicting his response to atezolizumab therapy?","In a Caucasian male diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy indicated a TMB of ""nan."" How should we interpret this finding in the context of predicting his response to atezolizumab therapy? Review the patient's Compass transcriptomic report with particular attention to markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Combine these molecular findings with the overall Compass score and the patient’s clinical history to create a detailed immunological profile. This integrated profile will help assess the patient's current immune status and forecast their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), a transcriptomic analysis from a bladder biopsy of the tumor immune microenvironment returned a TMB value of nan. How should we interpret this finding with regard to the likelihood of a positive response to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), a transcriptomic analysis from a bladder biopsy of the tumor immune microenvironment returned a TMB value of nan. How should we interpret this finding with regard to the likelihood of a positive response to Atezolizumab therapy? Examine the patient's Compass transcriptomic report with a focus on markers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This profile will aid in evaluating the patient's current immune status and in predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"A white male patient with bladder urothelial carcinoma underwent a kidney biopsy for transcriptomic profiling of his tumor immune microenvironment, which revealed a tumor mutational burden of 6.0. Based on these findings, how likely is it that he will respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma underwent a kidney biopsy for transcriptomic profiling of his tumor immune microenvironment, which revealed a tumor mutational burden of 6.0. Based on these findings, how likely is it that he will respond to Atezolizumab therapy? Review the patient’s Compass transcriptomic analysis by concentrating on markers for macrophage activation, interferon-gamma signaling, genomic integrity, cell growth, and cytotoxic T-cell activity. Combine these molecular details with the overall Compass score and the patient’s clinical history to construct a detailed immunological profile. This integrated profile will help assess the patient’s current immune function and forecast their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"A white female patient with bladder urothelial carcinoma has undergone transcriptomic profiling of her tumor immune microenvironment from a kidney biopsy, which indicated that the tumor mutational burden (TMB) is not available. Based on these findings, how should we assess her potential responsiveness to Atezolizumab therapy?","A white female patient with bladder urothelial carcinoma has undergone transcriptomic profiling of her tumor immune microenvironment from a kidney biopsy, which indicated that the tumor mutational burden (TMB) is not available. Based on these findings, how should we assess her potential responsiveness to Atezolizumab therapy? Examine the patient's Compass transcriptomic analysis with a focus on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the overall Compass score and the patient’s clinical history to create a comprehensive immunological profile. This profile will aid in evaluating the patient’s current immune function and in predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"I have a Black/African American male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a ureteral biopsy reported a tumor mutational burden (TMB) of ""nan."" Could you help assess the implications of this TMB result for his likely response to Atezolizumab therapy?","I have a Black/African American male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a ureteral biopsy reported a tumor mutational burden (TMB) of ""nan."" Could you help assess the implications of this TMB result for his likely response to Atezolizumab therapy? Review the patient's Compass transcriptomic data, paying close attention to biomarkers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Combine these molecular indicators with the overall Compass score and the patient’s clinical background to create a detailed immunological profile. This profile will help assess the patient’s immune status and predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"In a white female patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has reported a tumor mutational burden (TMB) value as ""nan."" How would you assess her potential response to Atezolizumab therapy?","In a white female patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has reported a tumor mutational burden (TMB) value as ""nan."" How would you assess her potential response to Atezolizumab therapy? Please examine the patient's Compass transcriptomic data, focusing specifically on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to generate a comprehensive immunological profile. This detailed profile will be used to evaluate the patient's immune status and forecast their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"In a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment analysis from a ureter biopsy shows a tumor mutational burden (TMB) of 4.0. Based on these findings, how might this patient respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment analysis from a ureter biopsy shows a tumor mutational burden (TMB) of 4.0. Based on these findings, how might this patient respond to Atezolizumab therapy? Review the patient's Compass transcriptomic profile with attention to markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular insights with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This profile will help assess the patient's immune status and predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"In a Caucasian male diagnosed with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis revealed a tumor mutational burden of 14 mutations per megabase. Based on this information, what is the likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male diagnosed with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis revealed a tumor mutational burden of 14 mutations per megabase. Based on this information, what is the likelihood of a favorable response to Atezolizumab therapy? Please evaluate the patient's Compass transcriptomic data, focusing on key markers such as those for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to formulate a comprehensive immunological profile. This detailed assessment will inform predictions about the patient’s immune status and guide expectations regarding their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, where the tumor immune microenvironment profile obtained from a lung biopsy shows a tumor mutation burden (TMB) of 7.0, could you assess the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, where the tumor immune microenvironment profile obtained from a lung biopsy shows a tumor mutation burden (TMB) of 7.0, could you assess the likelihood of a favorable response to Atezolizumab therapy? Review the patient’s Compass transcriptomic data with particular attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Please integrate these molecular details with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This evaluation will help us predict the patient’s immune status and anticipate their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"In a white female patient with bladder urothelial carcinoma (BLCA) and a lung biopsy showing a tumor microenvironment transcriptomic profile with a tumor mutational burden (TMB) of 3.0, how likely is she to respond to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma (BLCA) and a lung biopsy showing a tumor microenvironment transcriptomic profile with a tumor mutational burden (TMB) of 3.0, how likely is she to respond to Atezolizumab therapy? Please review the patient's Compass transcriptomic data, concentrating on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular findings with the overall Compass score and the patient’s clinical history to develop a detailed immunological profile. This comprehensive evaluation is intended to inform our understanding of the patient’s immune status and help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"In a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment profiling from a bladder biopsy shows a TMB of 11.0, how likely is it that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment profiling from a bladder biopsy shows a TMB of 11.0, how likely is it that he will respond to Atezolizumab therapy? Please examine the patient's Compass transcriptomic data with an emphasis on the markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. In addition, integrate this information with the overall Compass score and the patient's clinical history to create a comprehensive immunological profile. This analysis is essential for understanding the patient’s immune status and for predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"In a white female patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a tumor mutational burden (TMB) of 4.0. Based on these findings, how likely is she to respond to atezolizumab therapy?","In a white female patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a tumor mutational burden (TMB) of 4.0. Based on these findings, how likely is she to respond to atezolizumab therapy? Please review the patient's Compass transcriptomic data, paying particular attention to markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This integrated evaluation is crucial for understanding the patient's immune status and anticipating their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"For a white female patient with bladder urothelial carcinoma whose transcriptomic profile from a bladder biopsy indicates an indeterminate tumor mutation burden, how can we estimate her likelihood of responding to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma whose transcriptomic profile from a bladder biopsy indicates an indeterminate tumor mutation burden, how can we estimate her likelihood of responding to Atezolizumab therapy? Please evaluate the patient’s Compass transcriptomic data, focusing on markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these findings with the overall Compass score and the patient’s clinical history to construct a comprehensive immunological profile. This thorough analysis is essential for accurately assessing the patient's immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy did not yield a measurable tumor mutational burden. Based on this data, how likely is it that this patient will respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy did not yield a measurable tumor mutational burden. Based on this data, how likely is it that this patient will respond to Atezolizumab therapy? Please review the patient’s Compass transcriptomic results, giving particular attention to markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After this, correlate these results with the overall Compass score and the patient’s clinical history to develop a detailed immunological profile. This comprehensive evaluation is crucial for accurately determining the patient’s immune status and for predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"We have a white male patient with bladder urothelial carcinoma whose latest tumor biopsy revealed a tumor mutational burden of 18.0. Based on the transcriptomic profile of the tumor immune microenvironment, could this patient be expected to respond favorably to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma whose latest tumor biopsy revealed a tumor mutational burden of 18.0. Based on the transcriptomic profile of the tumor immune microenvironment, could this patient be expected to respond favorably to Atezolizumab therapy? Please examine the patient’s Compass transcriptomic data with a focus on markers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these findings with the overall Compass score and the patient’s clinical history to construct a detailed immunological profile. This thorough evaluation is essential for accurately determining the patient’s immune status and for predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"A Caucasian male patient with bladder urothelial carcinoma has a biopsy revealing a tumor mutational burden of 19.0. Based on this transcriptomic profile of the tumor immune microenvironment, how likely is the patient to respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a biopsy revealing a tumor mutational burden of 19.0. Based on this transcriptomic profile of the tumor immune microenvironment, how likely is the patient to respond to Atezolizumab therapy? Review the patient's Compass transcriptomic data, specifically evaluating markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This detailed analysis is crucial for accurately assessing the patient's immune status and predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 35. Could you evaluate his likelihood of responding to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 35. Could you evaluate his likelihood of responding to atezolizumab therapy? Evaluate the patient's Compass transcriptomic data by focusing on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these results with the overall Compass score and the patient's clinical history to construct a detailed immunological profile. This comprehensive analysis is essential for accurately determining the patient’s immune status and forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, revealing a tumor mutational burden (TMB) of 5.0. Based on these findings, what is the likelihood that this patient will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, revealing a tumor mutational burden (TMB) of 5.0. Based on these findings, what is the likelihood that this patient will respond to Atezolizumab therapy? Review the patient's Compass transcriptomic report by concentrating on markers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these specific findings with the overall Compass score and the patient’s clinical history to create a detailed immunological profile. This comprehensive evaluation is essential for precisely assessing the patient’s immune status and forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 5.0 mutations per megabase. How might this TMB level influence his likelihood of responding to Atezolizumab therapy?,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 5.0 mutations per megabase. How might this TMB level influence his likelihood of responding to Atezolizumab therapy? Review the patient’s Compass transcriptomic report with close attention to parameters related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these observations with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This detailed assessment is crucial for accurately evaluating the patient’s immune condition and predicting how they might respond to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden of 16.0. Based on these findings, how likely is it that the patient will respond favorably to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden of 16.0. Based on these findings, how likely is it that the patient will respond favorably to atezolizumab therapy? Examine the patient's Compass transcriptomic report, paying particular attention to metrics associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these findings with the overall Compass score and the patient’s clinical history to construct a comprehensive immunological profile. This detailed evaluation is essential for determining the patient’s immune status and for forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"I have a patient with bladder urothelial carcinoma whose transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutation burden of 8.0. Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutation burden of 8.0. Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy? Review the patient's Compass transcriptomic report with a focus on markers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these detailed findings with the overall Compass score and the patient's clinical history to create a comprehensive immunological profile. This analysis is vital for assessing the patient's immune status and predicting their potential response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"In a Caucasian patient with biopsy-confirmed bladder urothelial carcinoma exhibiting a tumor mutational burden of 5.0, how likely is it that the patient will respond favorably to Atezolizumab therapy?","In a Caucasian patient with biopsy-confirmed bladder urothelial carcinoma exhibiting a tumor mutational burden of 5.0, how likely is it that the patient will respond favorably to Atezolizumab therapy? Please examine the patient's Compass transcriptomic report, paying close attention to markers that indicate macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these detailed findings with the overall Compass score and the patient’s clinical history to construct a comprehensive immunological profile. This thorough assessment is critical for evaluating the patient’s immune status and determining their likely response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"A white female patient with bladder urothelial carcinoma has a tumor immune microenvironment profile based on kidney biopsy analysis, showing a tumor mutational burden of 5.0. Based on these findings, is she likely to respond to atezolizumab therapy?","A white female patient with bladder urothelial carcinoma has a tumor immune microenvironment profile based on kidney biopsy analysis, showing a tumor mutational burden of 5.0. Based on these findings, is she likely to respond to atezolizumab therapy? Review the patient's Compass transcriptomic report in detail, focusing specifically on indicators of macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This detailed evaluation is essential for assessing the patient’s immune status and predicting their response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis shows a tumor mutational burden of 7.0 mutations per megabase, what is the likelihood that she would respond favorably to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis shows a tumor mutational burden of 7.0 mutations per megabase, what is the likelihood that she would respond favorably to Atezolizumab therapy? Examine the patient's Compass transcriptomic report thoroughly, paying special attention to markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these results with the overall Compass score and the patient’s clinical history to construct a comprehensive immunological profile. This detailed analysis is crucial for evaluating the patient's immune status and estimating their potential response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy transcriptomic analysis did not yield a measurable tumor mutational burden, what is the likelihood of response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy transcriptomic analysis did not yield a measurable tumor mutational burden, what is the likelihood of response to Atezolizumab therapy? Review the patient's Compass transcriptomic report in detail, focusing on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these findings with the overall Compass score and the patient's clinical history to establish a complete immunological profile. This comprehensive assessment is essential for evaluating the patient’s immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"A Caucasian male patient with bladder urothelial carcinoma has a tumor transcriptomic profile showing a tumor mutational burden of 9.0. Based on this information, how likely is it that he will respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a tumor transcriptomic profile showing a tumor mutational burden of 9.0. Based on this information, how likely is it that he will respond to Atezolizumab therapy? Please carefully review the patient's Compass transcriptomic report, paying specific attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these findings with the overall Compass score and the patient's clinical history to assemble a comprehensive immunological profile. This detailed evaluation is critical for accurately assessing the patient's immune status and forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"We have a white female patient diagnosed with bladder urothelial carcinoma whose tumor immune microenvironment, profiled from a bladder biopsy, shows a tumor mutational burden of 20 mutations per megabase. How likely is she to respond to Atezolizumab therapy based on these findings?","We have a white female patient diagnosed with bladder urothelial carcinoma whose tumor immune microenvironment, profiled from a bladder biopsy, shows a tumor mutational burden of 20 mutations per megabase. How likely is she to respond to Atezolizumab therapy based on these findings? Review the patient's Compass transcriptomic report in detail, focusing on indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these findings with the overall Compass score and the patient's clinical history to develop a complete immunological profile. This thorough evaluation is essential for determining the patient's immune status and anticipating their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"For a Caucasian female patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutational burden (TMB) of 10 mutations per megabase. Based on this molecular data, what is her likelihood of responding favorably to atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutational burden (TMB) of 10 mutations per megabase. Based on this molecular data, what is her likelihood of responding favorably to atezolizumab therapy? Examine the patient's Compass transcriptomic report with emphasis on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these findings with the overall Compass score and the patient's clinical history to create a comprehensive immunological profile. This detailed assessment is crucial for accurately determining the patient’s immune status and forecasting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"In a White male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profiling shows a TMB of 35.0, what is the likelihood that he will respond to atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profiling shows a TMB of 35.0, what is the likelihood that he will respond to atezolizumab therapy? Review the patient's Compass transcriptomic report, paying special attention to markers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these observations with the overall Compass score and the patient's clinical history to construct a detailed immunological profile. This thorough evaluation is essential for accurately determining the patient's immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"For a Caucasian female patient with bladder urothelial carcinoma and a tumor mutational burden of 6.0 determined via transcriptomic profiling of the tumor microenvironment, what is the likelihood of a meaningful response to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma and a tumor mutational burden of 6.0 determined via transcriptomic profiling of the tumor microenvironment, what is the likelihood of a meaningful response to Atezolizumab therapy? Examine the patient's Compass transcriptomic report with a particular focus on indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This detailed assessment is critical for accurately evaluating the patient's immune status and forecasting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment, obtained from a bladder biopsy, revealed a tumor mutational burden of 3.0. Based on these findings, how likely is it that she will respond to Atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment, obtained from a bladder biopsy, revealed a tumor mutational burden of 3.0. Based on these findings, how likely is it that she will respond to Atezolizumab therapy? Review the patient's Compass transcriptomic report, paying close attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these findings with the overall Compass score and the patient’s clinical history to construct a detailed immunological profile. This comprehensive assessment is essential for accurately determining the patient’s immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"In a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutation burden of 5.0, how predictive is this profile for a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutation burden of 5.0, how predictive is this profile for a favorable response to Atezolizumab therapy? Please examine the patient's Compass transcriptomic report with a focus on evaluating markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these findings with the overall Compass score and the patient's clinical history to develop a comprehensive immunological profile. This detailed assessment is critical for accurately determining the patient's immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"For a Caucasian male diagnosed with bladder urothelial carcinoma, a nanobiopsy of the tumor immune microenvironment revealed a tumor mutational burden of 5.0. Based on this profile, how likely is he to respond to Atezolizumab therapy?","For a Caucasian male diagnosed with bladder urothelial carcinoma, a nanobiopsy of the tumor immune microenvironment revealed a tumor mutational burden of 5.0. Based on this profile, how likely is he to respond to Atezolizumab therapy? Review the patient's Compass transcriptomic report with particular attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these findings with the overall Compass score and the patient's clinical history to construct a detailed immunological profile. This comprehensive evaluation is essential for accurately assessing the patient’s immune status and predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has revealed a tumor mutational burden (TMB) of 5.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has revealed a tumor mutational burden (TMB) of 5.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Please review the patient’s Compass transcriptomic report, focusing on the markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these results with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This detailed assessment is crucial for accurately determining the patient’s immune status and predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"I have a white male patient with bladder urothelial carcinoma (BLCA). Transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy reveals a tumor mutational burden (TMB) of 5.0. Based on these findings, how likely is it that he will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA). Transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy reveals a tumor mutational burden (TMB) of 5.0. Based on these findings, how likely is it that he will respond to Atezolizumab therapy? Please examine the patient’s Compass transcriptomic report, paying close attention to markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After gathering this information, correlate these findings with the overall Compass score and the patient’s clinical history to create a comprehensive immunological profile. This detailed evaluation is essential for accurately assessing the patient’s immune status and predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"In a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reported a TMB value of ""nan."" Could you assess whether Atezolizumab therapy is likely to be effective in this patient?","In a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reported a TMB value of ""nan."" Could you assess whether Atezolizumab therapy is likely to be effective in this patient? Please review the patient’s Compass transcriptomic analysis with a focus on markers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you have gathered these details, integrate the findings with the overall Compass score and the patient’s clinical history to assemble a detailed immunological profile. This comprehensive assessment is critical for evaluating the patient’s immune status and anticipating their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"I have a patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 3.0 mutations per megabase. Based on this information, what is the likelihood that this patient will respond to atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 3.0 mutations per megabase. Based on this information, what is the likelihood that this patient will respond to atezolizumab therapy? Review the patient’s Compass transcriptomic analysis, paying close attention to indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these findings with the overall Compass score and the patient’s clinical history to formulate a comprehensive immunological profile. This detailed evaluation is essential for understanding the patient’s immune status and for predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A profile of his tumor immune microenvironment, obtained via a ureter biopsy, indicates a tumor mutational burden of 10.0 mutations per megabase. Based on these findings, is he likely to respond favorably to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A profile of his tumor immune microenvironment, obtained via a ureter biopsy, indicates a tumor mutational burden of 10.0 mutations per megabase. Based on these findings, is he likely to respond favorably to Atezolizumab therapy? Please review the patient’s Compass transcriptomic report, focusing specifically on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunological profile. This analysis is crucial for accurately assessing the patient’s immune status and for predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis from a lymph node biopsy shows a tumor mutational burden of 3.0. Based on this data, how likely is he to respond to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis from a lymph node biopsy shows a tumor mutational burden of 3.0. Based on this data, how likely is he to respond to Atezolizumab therapy? Review the patient's Compass transcriptomic report with special attention to markers for macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Integrate these specific findings with the overall Compass score and the patient’s clinical history to construct a detailed immunological profile. This comprehensive analysis is essential for accurately assessing the patient’s immune status and for forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 3.0 mutations per megabase. Based on this profile, how likely is it that the patient will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 3.0 mutations per megabase. Based on this profile, how likely is it that the patient will respond to Atezolizumab therapy? Examine the patient's Compass transcriptomic report, focusing on markers related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Combine these detailed findings with the overall Compass score and the patient's clinical history to create a comprehensive immunological profile. This analysis is crucial for accurately assessing the patient's immune status and predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"We have a Black or African American female patient with Bladder Urothelial Carcinoma (BLCA) who underwent a lung biopsy for transcriptomic profiling of her tumor immune microenvironment. The analysis revealed a tumor mutational burden (TMB) of 11.0. Based on these findings, how likely is it that she would respond to Atezolizumab therapy?","We have a Black or African American female patient with Bladder Urothelial Carcinoma (BLCA) who underwent a lung biopsy for transcriptomic profiling of her tumor immune microenvironment. The analysis revealed a tumor mutational burden (TMB) of 11.0. Based on these findings, how likely is it that she would respond to Atezolizumab therapy? Review the patient’s Compass transcriptomic report with particular attention to markers that indicate macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Next, integrate these findings with the overall Compass score and the patient's clinical history to develop a detailed immunological profile. This comprehensive evaluation is essential for accurately assessing the patient’s immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a lymph node biopsy indicated that the tumor mutation burden (TMB) was not available. Based on this information, could you advise on the potential efficacy of Atezolizumab therapy for this patient?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a lymph node biopsy indicated that the tumor mutation burden (TMB) was not available. Based on this information, could you advise on the potential efficacy of Atezolizumab therapy for this patient? Please review the patient's Compass transcriptomic report, paying special attention to markers that reflect macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Then, combine these results with the overall Compass score and the patient's clinical history to construct a detailed immunological profile. This thorough evaluation is critical for accurately assessing the patient's immune status and forecasting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"A white male patient with bladder urothelial carcinoma has undergone transcriptomic profiling of the tumor immune microenvironment from a liver biopsy, which resulted in a tumor mutational burden (TMB) measurement of ""nan."" Based on this information, can we determine if this patient is likely to respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has undergone transcriptomic profiling of the tumor immune microenvironment from a liver biopsy, which resulted in a tumor mutational burden (TMB) measurement of ""nan."" Based on this information, can we determine if this patient is likely to respond to Atezolizumab therapy? Review the patient's Compass transcriptomic report with particular emphasis on markers indicating macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to create a comprehensive immunologic profile. This thorough assessment is essential for accurately evaluating the patient’s immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"This white female patient has been diagnosed with bladder urothelial carcinoma (BLCA), and analysis of the tumor immune microenvironment from a ureter biopsy reveals a tumor mutational burden (TMB) of 26. Based on these findings, how likely is it that the patient will respond favorably to Atezolizumab therapy?","This white female patient has been diagnosed with bladder urothelial carcinoma (BLCA), and analysis of the tumor immune microenvironment from a ureter biopsy reveals a tumor mutational burden (TMB) of 26. Based on these findings, how likely is it that the patient will respond favorably to Atezolizumab therapy? Please review the patient’s Compass transcriptomic report, focusing specifically on markers of macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Combine these molecular insights with the overall Compass score and the patient’s clinical history to develop a complete immunologic profile. This comprehensive evaluation is critical for accurately assessing the patient’s immune status and forecasting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A biopsy of his tumor revealed a transcriptomic profile with a tumor mutational burden of 14 mutations per megabase. Based on these findings, what is your assessment of his likelihood to respond to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A biopsy of his tumor revealed a transcriptomic profile with a tumor mutational burden of 14 mutations per megabase. Based on these findings, what is your assessment of his likelihood to respond to atezolizumab therapy? Please examine the patient’s Compass transcriptomic report with an emphasis on specific molecular markers: macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular details with the overall Compass score and the patient’s clinical history to create a thorough immunologic profile. This detailed evaluation is essential for accurately determining the patient's immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"In a white male patient with bladder urothelial carcinoma, a lung biopsy of the tumor immune microenvironment yielded a transcriptomic profile with a tumor mutation burden reported as NaN. Based on these findings, can we reliably predict his likelihood of responding to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a lung biopsy of the tumor immune microenvironment yielded a transcriptomic profile with a tumor mutation burden reported as NaN. Based on these findings, can we reliably predict his likelihood of responding to Atezolizumab therapy? Review the patient’s Compass transcriptomic report with particular attention to markers indicating macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Combine these findings with the overall Compass score and the patient’s clinical history to develop a detailed immunologic profile. This comprehensive evaluation is critical for accurately assessing the patient's immune status and forecasting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"A Caucasian female patient diagnosed with bladder urothelial carcinoma has a tumor mutational burden of 4.0, as determined by transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy. Based on this information, how likely is she to respond to atezolizumab therapy?","A Caucasian female patient diagnosed with bladder urothelial carcinoma has a tumor mutational burden of 4.0, as determined by transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy. Based on this information, how likely is she to respond to atezolizumab therapy? Review the patient’s Compass transcriptomic report, concentrating on markers for macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Integrate these findings with the overall Compass score and the patient’s clinical history to construct a detailed immunologic profile. This thorough evaluation is essential for accurately assessing the patient’s immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma, tumor biopsy transcriptomic analysis reveals a tumor mutational burden of 3.0. Based on this information, what is the anticipated response to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, tumor biopsy transcriptomic analysis reveals a tumor mutational burden of 3.0. Based on this information, what is the anticipated response to atezolizumab therapy? Examine the patient's Compass transcriptomic report with a focus on markers related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Combine these results with the overall Compass score and the patient’s clinical history to create a comprehensive immunologic profile. This detailed analysis is crucial for accurately evaluating the patient's immune status and forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"For a white male patient with bladder urothelial carcinoma, whose transcriptomic analysis from a bladder biopsy shows a tumor mutational burden of 22, how likely is it that he will respond favorably to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose transcriptomic analysis from a bladder biopsy shows a tumor mutational burden of 22, how likely is it that he will respond favorably to atezolizumab therapy? Review the patient's Compass transcriptomic report, focusing on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these findings with the overall Compass score and the clinical history to generate a complete immunologic profile. This detailed evaluation is essential for accurately assessing the patient’s immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) value reported as ""nan."" How should this result be interpreted in terms of predicting his potential response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) value reported as ""nan."" How should this result be interpreted in terms of predicting his potential response to Atezolizumab therapy? Please review the patient’s Compass transcriptomic report, paying particular attention to markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these observations with the overall Compass score and the patient’s clinical history to develop a comprehensive immunologic profile. This step is critical for accurately determining the patient’s immune status and for predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"For a Caucasian female patient with bladder urothelial carcinoma, whose tumor immune microenvironment analysis from a lymph node biopsy indicates a tumor mutation burden of 3.0, what is the anticipated response to atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, whose tumor immune microenvironment analysis from a lymph node biopsy indicates a tumor mutation burden of 3.0, what is the anticipated response to atezolizumab therapy? Review the patient’s Compass transcriptomic report with a focus on evaluating markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these specific findings with the overall Compass score and the patient’s clinical history to construct a detailed immunologic profile. This analysis is essential for accurately assessing the patient’s immune status and anticipating their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment—obtained from a kidney biopsy—revealed a tumor mutational burden of 62. Based on these findings, is there evidence to suggest that the patient may respond favorably to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment—obtained from a kidney biopsy—revealed a tumor mutational burden of 62. Based on these findings, is there evidence to suggest that the patient may respond favorably to atezolizumab therapy? Review the patient’s Compass transcriptomic report, paying particular attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, merge these findings with the overall Compass score and the patient’s clinical history to formulate a comprehensive immunologic profile. This detailed assessment is crucial for accurately evaluating the patient’s immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"In a patient with bladder urothelial carcinoma whose transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 14.0, what is the likelihood of a favorable response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma whose transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 14.0, what is the likelihood of a favorable response to Atezolizumab therapy? Examine the patient’s Compass transcriptomic report with a focus on indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these data points with the overall Compass score and the patient’s clinical history to develop a detailed immunologic profile. This thorough assessment will be critical for accurately determining the patient’s immune status and forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"For a white male patient diagnosed with bladder urothelial carcinoma, with tumor immune microenvironment profiling from a lymph node biopsy showing a TMB of 7.0, what is the anticipated response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, with tumor immune microenvironment profiling from a lymph node biopsy showing a TMB of 7.0, what is the anticipated response to Atezolizumab therapy? Review the patient's Compass transcriptomic report, giving particular attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these findings with the overall Compass score and the patient’s clinical history to construct a comprehensive immunologic profile. This detailed evaluation is essential for accurately assessing the patient's immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"For a patient with bladder urothelial carcinoma whose tumor biopsy shows a transcriptomic profile with a TMB of 15.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a patient with bladder urothelial carcinoma whose tumor biopsy shows a transcriptomic profile with a TMB of 15.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please examine the patient’s Compass transcriptomic report, focusing especially on indicators related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Combine these results with the overall Compass score and the patient’s clinical history to develop a detailed immunologic profile. This thorough evaluation is critical for accurately assessing the immune status and anticipating the patient’s response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"In a Caucasian male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy indicates a tumor mutational burden of 5.0. Based on this information, what is the potential likelihood that the patient will respond to Atezolizumab therapy?","In a Caucasian male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy indicates a tumor mutational burden of 5.0. Based on this information, what is the potential likelihood that the patient will respond to Atezolizumab therapy? Review the patient’s Compass transcriptomic report with special attention to markers of macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Integrate these findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunologic profile. This detailed assessment is essential for accurately evaluating immune status and forecasting the patient’s response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed that the tumor mutational burden (TMB) is reported as ""nan."" Based on this information, can we assess whether he is likely to respond to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed that the tumor mutational burden (TMB) is reported as ""nan."" Based on this information, can we assess whether he is likely to respond to atezolizumab therapy? Please review the patient's Compass transcriptomic report, focusing on indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Combine these findings with the overall Compass score and the patient’s clinical history to form a detailed immunologic profile. This comprehensive evaluation is critical for accurately assessing the patient's immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"We have a White female patient diagnosed with Bladder Urothelial Carcinoma (BLCA). Transcriptomic profiling of her tumor immune microenvironment from a ureter biopsy did not yield a measurable tumor mutational burden (TMB). Given these findings, how likely is it that she will respond to Atezolizumab therapy?","We have a White female patient diagnosed with Bladder Urothelial Carcinoma (BLCA). Transcriptomic profiling of her tumor immune microenvironment from a ureter biopsy did not yield a measurable tumor mutational burden (TMB). Given these findings, how likely is it that she will respond to Atezolizumab therapy? Review the patient's Compass transcriptomic report with a focus on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these findings with the overall Compass score and the patient's clinical history to develop a detailed immunologic profile. This thorough evaluation is essential for accurately assessing the patient's immune status and anticipating their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 24. Could you provide insights on the likelihood of a favorable response to atezolizumab therapy based on these findings?","In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 24. Could you provide insights on the likelihood of a favorable response to atezolizumab therapy based on these findings? Please carefully examine the patient's Compass transcriptomic report with particular attention to markers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, correlate these results with the overall Compass score and the patient's clinical history to construct a comprehensive immunologic profile. This detailed analysis is crucial for accurately assessing the patient’s immune status and for predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed an indeterminate tumor mutational burden. Based on this information, can we predict his likely response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed an indeterminate tumor mutational burden. Based on this information, can we predict his likely response to Atezolizumab therapy? Please review the patient's Compass transcriptomic report, focusing on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Next, integrate these findings with the overall Compass score and the patient's clinical history to develop a detailed immunologic profile. This thorough evaluation is essential for accurately determining the patient's immune status and forecasting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A ureteral biopsy provided a transcriptomic profile of the tumor immune microenvironment, indicating a tumor mutational burden (TMB) of 8.0 mutations per megabase. Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A ureteral biopsy provided a transcriptomic profile of the tumor immune microenvironment, indicating a tumor mutational burden (TMB) of 8.0 mutations per megabase. Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy? Please review the patient’s Compass transcriptomic report with a focus on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these details with the overall Compass score and the patient’s clinical history to construct a comprehensive immunologic profile. This detailed evaluation is crucial for accurately assessing the patient’s immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"A white male patient with bladder urothelial carcinoma has undergone a kidney biopsy, and the transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutation burden of 4.0. Based on these findings, can we predict whether the patient is likely to respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has undergone a kidney biopsy, and the transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutation burden of 4.0. Based on these findings, can we predict whether the patient is likely to respond to Atezolizumab therapy? Review the patient’s Compass transcriptomic report by specifically examining markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these findings with the overall Compass score and the patient’s clinical history to develop a detailed immunologic profile. This assessment is essential for accurately determining the patient's immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 14.0 obtained from transcriptomic analysis of the tumor immune microenvironment, what is the likelihood of a favorable clinical response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 14.0 obtained from transcriptomic analysis of the tumor immune microenvironment, what is the likelihood of a favorable clinical response to atezolizumab therapy? Examine the patient's Compass transcriptomic analysis with a focus on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these findings with the overall Compass score and the patient’s clinical history to construct a detailed immunologic profile. This comprehensive evaluation is crucial for accurately assessing the patient’s immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden (TMB) of 5.0 mutations per megabase, what is the likelihood of a therapeutic response to Atezolizumab?","For a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden (TMB) of 5.0 mutations per megabase, what is the likelihood of a therapeutic response to Atezolizumab? Review the patient's Compass transcriptomic analysis, specifically evaluating markers for macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Then, integrate these findings with the overall Compass score and the patient’s clinical history to develop a detailed immunologic profile. This comprehensive assessment will help accurately gauge the patient's immune status and predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose transcriptomic profile from a bladder biopsy shows a tumor mutational burden of 10.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose transcriptomic profile from a bladder biopsy shows a tumor mutational burden of 10.0, what is the likelihood of a favorable response to atezolizumab therapy? Please review the patient's Compass transcriptomic analysis, paying close attention to markers associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Next, combine these molecular findings with the overall Compass score and the patient’s clinical history to create a comprehensive immunologic profile. This detailed evaluation is intended to accurately determine the patient’s immune status and forecast their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"A Caucasian male with bladder urothelial carcinoma underwent transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden (TMB) was reported as ‘nan.’ How should we interpret this result in relation to his potential response to Atezolizumab therapy?","A Caucasian male with bladder urothelial carcinoma underwent transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden (TMB) was reported as ‘nan.’ How should we interpret this result in relation to his potential response to Atezolizumab therapy? Review the patient's Compass transcriptomic analysis with emphasis on markers for macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Then, integrate these molecular findings with the overall Compass score and the patient’s clinical history to develop a comprehensive immunologic profile. This step-by-step evaluation will help us accurately assess the patient's immune status and predict their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"We have a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment was analyzed via a lymph node biopsy. The assessment reported a tumor mutational burden (TMB) value of ""nan."" Could this result inform us about the likelihood of a positive response to Atezolizumab therapy?","We have a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment was analyzed via a lymph node biopsy. The assessment reported a tumor mutational burden (TMB) value of ""nan."" Could this result inform us about the likelihood of a positive response to Atezolizumab therapy? Please review the patient's Compass transcriptomic analysis with a focus on markers indicating macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Next, combine these molecular insights with the overall Compass score and the patient’s clinical history to develop a detailed immunologic profile. This step‐by‐step approach will enhance our ability to accurately evaluate the patient’s immune status and predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"A Caucasian male patient diagnosed with bladder urothelial carcinoma has a tumor mutation burden of 19.0, as determined from a transcriptomic analysis of the tumor microenvironment via bladder biopsy. Based on these findings, what is the likelihood that the patient will respond favorably to atezolizumab therapy?","A Caucasian male patient diagnosed with bladder urothelial carcinoma has a tumor mutation burden of 19.0, as determined from a transcriptomic analysis of the tumor microenvironment via bladder biopsy. Based on these findings, what is the likelihood that the patient will respond favorably to atezolizumab therapy? Review the patient's Compass transcriptomic report, concentrating on biomarkers for macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Then, integrate these molecular findings with the overall Compass score and the patient's clinical history to construct a comprehensive immunologic profile. This methodical evaluation will improve our assessment of the patient's immune status and our ability to predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"For a female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden (TMB) of 5.0. Based on this profile, what is the likelihood of this patient responding to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden (TMB) of 5.0. Based on this profile, what is the likelihood of this patient responding to Atezolizumab therapy? Review the patient's Compass transcriptomic report, paying specific attention to biomarkers that indicate macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Then, combine these molecular insights with the overall Compass score and the patient’s clinical history to create a comprehensive immunologic profile. This systematic approach will enhance our evaluation of the patient’s immune status and improve our ability to estimate their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), whose bladder biopsy shows a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden of 2.0, is there evidence to suggest that she would likely respond to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), whose bladder biopsy shows a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden of 2.0, is there evidence to suggest that she would likely respond to Atezolizumab therapy? Review the patient's Compass transcriptomic report with an emphasis on biomarkers that signal macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Integrate these molecular findings with both the overall Compass score and the patient’s clinical history to develop a thorough immunologic profile. This systematic process will improve our assessment of the patient's immune status and help us better estimate their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"In a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from the bladder biopsy revealed a tumor mutational burden (TMB) of 14.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from the bladder biopsy revealed a tumor mutational burden (TMB) of 14.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please evaluate the patient’s Compass transcriptomic report, focusing on biomarkers that indicate macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Combine these molecular insights with the overall Compass score and the patient’s clinical history to construct a detailed immunologic profile. This systematic evaluation will enhance our understanding of the patient’s immune status and inform our predictions regarding their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. Her tumor immune microenvironment has been profiled via nanobiopsy, revealing a tumor mutational burden of 17.0. Could you evaluate her likelihood of responding favorably to Atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. Her tumor immune microenvironment has been profiled via nanobiopsy, revealing a tumor mutational burden of 17.0. Could you evaluate her likelihood of responding favorably to Atezolizumab therapy? Please review the patient’s Compass transcriptomic report with particular attention to biomarkers related to macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to create a comprehensive immunologic profile. This detailed assessment will help us better understand the patient’s immune status and improve our predictions regarding their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) reported as ""nan."" Based on this finding, how might we expect the patient to respond to Atezolizumab therapy?","We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) reported as ""nan."" Based on this finding, how might we expect the patient to respond to Atezolizumab therapy? Please examine the patient's Compass transcriptomic report with a focus on biomarkers associated with macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Combine these molecular details with the overall Compass score and the patient’s clinical history to develop a comprehensive profile of their immune status. This evaluation is essential for enhancing our understanding of the patient’s immunologic landscape and for refining our predictions regarding their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) whose tumor transcriptomic profile from a biopsy indicates a tumor mutational burden (TMB) of 6.0, what is the likelihood that he may respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) whose tumor transcriptomic profile from a biopsy indicates a tumor mutational burden (TMB) of 6.0, what is the likelihood that he may respond favorably to Atezolizumab therapy? Please review the patient's Compass transcriptomic report, specifically focusing on biomarkers related to macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Integrate these molecular findings with the overall Compass score and the patient's clinical history to develop a detailed assessment of their immune status. This comprehensive analysis is aimed at enhancing our understanding of the patient's immunologic profile and improving our predictions regarding their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"A white female patient with bladder urothelial carcinoma (BLCA) has a tumor microenvironment biopsy showing a tumor mutational burden (TMB) of 9.0. Based on this transcriptomic profile, how likely is she to benefit from Atezolizumab therapy?","A white female patient with bladder urothelial carcinoma (BLCA) has a tumor microenvironment biopsy showing a tumor mutational burden (TMB) of 9.0. Based on this transcriptomic profile, how likely is she to benefit from Atezolizumab therapy? Please examine the patient’s Compass transcriptomic report and focus on the biomarkers associated with macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Combine these molecular findings with the overall Compass score and the patient’s clinical history to develop a detailed evaluation of their immune profile. This integrated analysis will enhance our understanding of the patient’s immunologic status and help predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled from a kidney biopsy and shows a tumor mutational burden of 5.0, what is her likelihood of responding to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled from a kidney biopsy and shows a tumor mutational burden of 5.0, what is her likelihood of responding to Atezolizumab therapy? Review the patient's Compass transcriptomic report, paying special attention to biomarkers related to macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Then, integrate these molecular findings with the overall Compass score and the patient's clinical history to construct a comprehensive evaluation of their immune profile. This thorough analysis will provide insight into their immunologic status and help forecast their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"Considering a white male patient with bladder urothelial carcinoma (BLCA), whose liver biopsy transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 5.0, could you provide insight into whether Atezolizumab therapy is likely to be effective in this case?","Considering a white male patient with bladder urothelial carcinoma (BLCA), whose liver biopsy transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 5.0, could you provide insight into whether Atezolizumab therapy is likely to be effective in this case? Please examine the patient's Compass transcriptomic report, focusing on biomarkers that indicate macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Combine these molecular findings with the overall Compass score and the patient's clinical history to develop a comprehensive assessment of their immune profile. This detailed evaluation will help us understand their immunologic status and predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment obtained via bladder biopsy indicated a tumor mutational burden (TMB) value of ""nan."" How should this finding be interpreted in the context of his potential response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment obtained via bladder biopsy indicated a tumor mutational burden (TMB) value of ""nan."" How should this finding be interpreted in the context of his potential response to Atezolizumab therapy? Review the patient's Compass transcriptomic report with attention to biomarkers associated with macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Combine these molecular details with the overall Compass score and the patient’s clinical history to create a thorough evaluation of their immune profile. This comprehensive assessment will help determine their immunologic status and forecast their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e71235-ar-e712352.pkl. "
BLCA,,,,NR,I have a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was analyzed using transcriptomic profiling from a kidney biopsy. The report indicates that the tumor mutational burden (TMB) is not available (nan). Could you assess the likelihood of his responding to atezolizumab therapy?,"I have a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was analyzed using transcriptomic profiling from a kidney biopsy. The report indicates that the tumor mutational burden (TMB) is not available (nan). Could you assess the likelihood of his responding to atezolizumab therapy? Examine the patient’s Compass transcriptomic report, focusing specifically on biomarkers related to macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Integrate these molecular findings with the overall Compass score and the patient’s clinical history to develop a comprehensive evaluation of their immune profile. This detailed assessment will be instrumental in determining the patient’s immunologic status and in predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"I am managing a Caucasian male patient with bladder urothelial carcinoma. A kidney biopsy of his tumor immune microenvironment revealed a tumor mutational burden of 7.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I am managing a Caucasian male patient with bladder urothelial carcinoma. A kidney biopsy of his tumor immune microenvironment revealed a tumor mutational burden of 7.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Review the patient's Compass transcriptomic report with particular attention to biomarkers indicating macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Combine these molecular data with the overall Compass score and the patient’s clinical history to construct a detailed evaluation of their immune profile. This comprehensive assessment will help clarify the patient’s immunologic status and guide predictions about their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, a tumor biopsy revealed a transcriptomic immune microenvironment profile with a tumor mutational burden (TMB) of 1.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a tumor biopsy revealed a transcriptomic immune microenvironment profile with a tumor mutational burden (TMB) of 1.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Examine the patient's Compass transcriptomic report in detail, with a focus on markers of macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Integrate these molecular findings with the overall Compass score and the patient's clinical history to develop a comprehensive evaluation of their immune profile. This analysis will assist in clarifying the patient’s immunologic status and in predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment via a bladder biopsy. The analysis reported a tumor mutation burden (TMB) value of ""nan."" Could you provide insights on the likelihood of this patient responding favorably to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment via a bladder biopsy. The analysis reported a tumor mutation burden (TMB) value of ""nan."" Could you provide insights on the likelihood of this patient responding favorably to Atezolizumab therapy? Review the patient's Compass transcriptomic report thoroughly, paying particular attention to markers of macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Combine these molecular insights with the overall Compass score and the patient's clinical history to construct a detailed assessment of their immune profile. This evaluation will help clarify the patient's immunologic status and inform predictions regarding their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. The tumor immune microenvironment was characterized via transcriptomic profiling from a bladder biopsy, revealing a tumor mutational burden (TMB) of 6.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. The tumor immune microenvironment was characterized via transcriptomic profiling from a bladder biopsy, revealing a tumor mutational burden (TMB) of 6.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Please conduct a comprehensive review of the patient's Compass transcriptomic report, with focused attention on markers for macrophage activation, interferon‑gamma signaling, genomic integrity, cell proliferation, and cytotoxic T‑cell activity. Integrate these molecular findings with the overall Compass score and the patient's clinical history to develop a detailed immune profile. This analysis will elucidate the patient's immunologic status and help forecast their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,I am evaluating a Caucasian female patient diagnosed with bladder urothelial carcinoma. Her bladder biopsy reveals a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden (TMB) of 3.0. Could you assess the likelihood that she will respond favorably to Atezolizumab therapy?,"I am evaluating a Caucasian female patient diagnosed with bladder urothelial carcinoma. Her bladder biopsy reveals a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden (TMB) of 3.0. Could you assess the likelihood that she will respond favorably to Atezolizumab therapy? Please review the patient's Compass transcriptomic report in detail, paying special attention to markers associated with macrophage activation, interferon‑gamma signaling, genomic integrity, cell proliferation, and cytotoxic T‑cell activity. Then, combine these molecular insights with the overall Compass score and the patient's clinical history to construct a thorough immune profile. This evaluation will clarify the patient's immunologic status and assist in predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 7.0. Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 7.0. Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy? Please examine the patient's Compass transcriptomic report carefully. Focus on identifying markers linked to macrophage activation, interferon‑gamma signaling, genomic integrity, cell proliferation, and cytotoxic T‑cell activity. Next, integrate these molecular findings with the overall Compass score and the patient's clinical history to develop a comprehensive immune profile. This detailed evaluation is intended to clarify the patient’s immune status and help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 14.0. What is the likelihood that this patient will respond to atezolizumab therapy based on these findings?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 14.0. What is the likelihood that this patient will respond to atezolizumab therapy based on these findings? Review the patient's Compass transcriptomic report thoroughly. Pay particular attention to markers related to macrophage activation, interferon‑gamma signaling, genomic integrity, cell proliferation, and cytotoxic T‑cell function. Then, combine these molecular results with the overall Compass score and the patient's clinical history to create a comprehensive profile of their immune status. This integrated analysis will help clarify the patient’s immune condition and assist in predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via a kidney biopsy, revealing a tumor mutational burden of 2.0. Based on these results, how likely is he to respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via a kidney biopsy, revealing a tumor mutational burden of 2.0. Based on these results, how likely is he to respond to Atezolizumab therapy? Evaluate the patient's Compass transcriptomic report carefully. Focus specifically on markers associated with macrophage activation, interferon‑gamma signaling, genomic integrity, cell proliferation, and cytotoxic T‑cell activity. Once these molecular details have been identified, integrate them with the overall Compass score and the patient's clinical history to construct a comprehensive profile of their immune status. This holistic analysis is intended to clarify the patient’s immune condition and inform predictions regarding their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,I have a Caucasian male patient with bladder urothelial carcinoma who underwent a bladder biopsy for transcriptomic profiling of the tumor immune microenvironment. The analysis reported a tumor mutational burden of 'nan.' Could you help determine whether this result suggests that the patient is likely to respond to Atezolizumab therapy?,"I have a Caucasian male patient with bladder urothelial carcinoma who underwent a bladder biopsy for transcriptomic profiling of the tumor immune microenvironment. The analysis reported a tumor mutational burden of 'nan.' Could you help determine whether this result suggests that the patient is likely to respond to Atezolizumab therapy? Review the Compass transcriptomic report with attention to markers of macrophage activation, interferon‑gamma signaling, genomic integrity, cell proliferation, and cytotoxic T‑cell activity. Once these markers are identified, integrate their results with the overall Compass score and the patient’s clinical history to develop a comprehensive immune profile. This integrated assessment will help clarify the patient’s immune status and facilitate predictions regarding their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"In a white patient with bladder urothelial carcinoma, a lymph node biopsy transcriptomic analysis of the tumor immune microenvironment reported a TMB value of ""nan."" How might this finding affect the likelihood of a positive response to atezolizumab therapy?","In a white patient with bladder urothelial carcinoma, a lymph node biopsy transcriptomic analysis of the tumor immune microenvironment reported a TMB value of ""nan."" How might this finding affect the likelihood of a positive response to atezolizumab therapy? Please review the Compass transcriptomic report with attention to markers that indicate macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Once identified, combine these findings with the overall Compass score and the patient’s clinical history to create a comprehensive immune profile. This integrated analysis will help determine the patient’s immune status and assist in predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who underwent a lung biopsy with transcriptomic profiling of the tumor immune microenvironment, and whose tumor mutation burden (TMB) is reported as 1.0, how likely is he to respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who underwent a lung biopsy with transcriptomic profiling of the tumor immune microenvironment, and whose tumor mutation burden (TMB) is reported as 1.0, how likely is he to respond to Atezolizumab therapy? Review the Compass transcriptomic report, focusing specifically on markers for macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. After identifying these features, integrate them with the overall Compass score and the patient's clinical history to develop a detailed immune profile. This comprehensive analysis will help assess the patient’s immune status and predict their responsiveness to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,We have a Caucasian patient with bladder urothelial carcinoma (BLCA) whose ureter biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden (TMB) of 14.0. Could this molecular profile indicate a favorable response to Atezolizumab therapy?,"We have a Caucasian patient with bladder urothelial carcinoma (BLCA) whose ureter biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden (TMB) of 14.0. Could this molecular profile indicate a favorable response to Atezolizumab therapy? Examine the Compass transcriptomic report, giving careful attention to markers indicating macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Then, correlate these findings with the overall Compass score and the patient’s clinical history to construct a comprehensive immune profile. This integrated analysis will aid in determining the patient’s current immune status and forecasting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"For a white male patient with bladder urothelial carcinoma whose tumor microenvironment analysis (from a kidney biopsy) revealed a tumor mutational burden of 14.0, how likely is it that he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose tumor microenvironment analysis (from a kidney biopsy) revealed a tumor mutational burden of 14.0, how likely is it that he will respond to Atezolizumab therapy? Please review the Compass transcriptomic report with a focus on markers for macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. After identifying these key markers, integrate the results with the overall Compass score and the patient’s clinical history to create a detailed immune profile. This comprehensive evaluation will help you assess the current state of the patient's immune system and predict their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"Given an African American patient with bladder urothelial carcinoma and a tumor mutational burden of 9.0 based on transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that this patient will respond to Atezolizumab therapy?","Given an African American patient with bladder urothelial carcinoma and a tumor mutational burden of 9.0 based on transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that this patient will respond to Atezolizumab therapy? Review the Compass transcriptomic report, paying special attention to markers related to macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Once you have identified these markers, combine these findings with the overall Compass score and the patient's clinical history to construct a detailed immune profile. This integrated analysis will assist you in evaluating the patient's current immune status and estimating their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"A Caucasian male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 8.0, as determined from a transcriptomic analysis of his bladder biopsy. Based on these findings, is he likely to respond favorably to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 8.0, as determined from a transcriptomic analysis of his bladder biopsy. Based on these findings, is he likely to respond favorably to atezolizumab therapy? Examine the Compass transcriptomic report, focusing specifically on markers for macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Once you have gathered this information, integrate it with the overall Compass score and the patient’s clinical history to develop a comprehensive immune profile. This synthesis will help you determine the patient’s current immune status and assess their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"In a white female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 7.0. How predictive is this TMB level for her response to Atezolizumab therapy?","In a white female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 7.0. How predictive is this TMB level for her response to Atezolizumab therapy? Review the Compass transcriptomic report with a focus on macrophage activation markers, interferon‑gamma signaling pathways, indicators of genomic stability, cell proliferation metrics, and cytotoxic T‑cell activity. After gathering these details, incorporate the results with the overall Compass score and the patient’s clinical history to establish a comprehensive immune profile. This integrated analysis will aid in determining the patient’s current immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"I have an Asian female patient with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment, derived from a kidney biopsy, revealed a tumor mutational burden (TMB) of 4.0. Based on these findings, how likely is she to respond to Atezolizumab therapy?","I have an Asian female patient with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment, derived from a kidney biopsy, revealed a tumor mutational burden (TMB) of 4.0. Based on these findings, how likely is she to respond to Atezolizumab therapy? Please review the Compass transcriptomic report, concentrating specifically on macrophage activation markers, interferon‑gamma signaling, genomic stability indicators, cell proliferation measures, and cytotoxic T‑cell activity. Once you have extracted these data, integrate them with the overall Compass score and the patient’s clinical history to develop a detailed immune profile. This comprehensive evaluation will help determine the patient’s current immune status and forecast their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment, obtained via kidney biopsy, revealed a tumor mutation burden (TMB) of 7.0 mutations per megabase. Based on these findings, can we expect a favorable response to Atezolizumab therapy?","We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment, obtained via kidney biopsy, revealed a tumor mutation burden (TMB) of 7.0 mutations per megabase. Based on these findings, can we expect a favorable response to Atezolizumab therapy? Review the Compass transcriptomic report with attention to key areas: macrophage activation markers, interferon‑gamma signaling pathways, genomic stability markers, cell proliferation indices, and cytotoxic T‑cell activity. Extract and consolidate these data points, then integrate them with the overall Compass score and the patient's clinical history to construct a comprehensive immune profile. This detailed evaluation will assist in assessing the patient's current immune status and in predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"For a white male patient with bladder urothelial carcinoma whose tumor transcriptomic analysis from a biopsy indicates a tumor mutational burden (TMB) reported as ""nan,"" could you provide an assessment of his likelihood to benefit from Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose tumor transcriptomic analysis from a biopsy indicates a tumor mutational burden (TMB) reported as ""nan,"" could you provide an assessment of his likelihood to benefit from Atezolizumab therapy? Examine the Compass transcriptomic report with a focus on key components: markers of macrophage activation, interferon‑gamma signaling pathways, indicators of genomic stability, measures of cell proliferation, and assessments of cytotoxic T‑cell activity. Summarize these findings and combine them with the overall Compass score and the patient’s clinical history to develop a detailed immune profile. This comprehensive evaluation is essential for determining the current state of the patient’s immune system and for predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"We have a white male patient with biopsy-confirmed bladder urothelial carcinoma (BLCA), and transcriptomic profiling of his tumor immune microenvironment indicates a tumor mutational burden (TMB) of 5.0. Could you comment on the potential responsiveness of this patient to Atezolizumab therapy based on these findings?","We have a white male patient with biopsy-confirmed bladder urothelial carcinoma (BLCA), and transcriptomic profiling of his tumor immune microenvironment indicates a tumor mutational burden (TMB) of 5.0. Could you comment on the potential responsiveness of this patient to Atezolizumab therapy based on these findings? Review the Compass transcriptomic report with emphasis on the following components: markers of macrophage activation, interferon‑gamma signaling pathways, genomic stability indicators, cell proliferation rates, and cytotoxic T‑cell activity. Summarize these findings and integrate them with the overall Compass score along with the patient's clinical history. This detailed immune profile is crucial for assessing the current status of the patient's immune system and for forecasting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"In a white female patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden of 7.0. Based on these findings, what is the likelihood that this patient will respond to Atezolizumab therapy?","In a white female patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden of 7.0. Based on these findings, what is the likelihood that this patient will respond to Atezolizumab therapy? Please review the Compass transcriptomic report, focusing on markers related to macrophage activation, interferon‑gamma signaling pathways, indicators of genomic stability, cell proliferation rates, and cytotoxic T‑cell activity. After summarizing these findings, integrate them with the overall Compass score and the patient’s clinical history. This comprehensive immune profiling is essential for evaluating the patient's current immune status and predicting their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a separate biopsy revealed a tumor mutational burden of 10 mutations per megabase. Based on this information, what is the likely response to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a separate biopsy revealed a tumor mutational burden of 10 mutations per megabase. Based on this information, what is the likely response to Atezolizumab therapy? Review the Compass transcriptomic report with attention to markers for macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Summarize these findings and incorporate them with the overall Compass score and the patient's clinical history. This detailed immune profiling is crucial for assessing the patient's current immune status and predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ffa5c7-ar-ffa5c7c.pkl. "
